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One crucial step in understanding the biological mechanism underlying a disease con-
dition is to capture the relationship between the variants and the disease risk [96]. There
are several publicly available databases contain the disease-associated variants such as
UMD [15], Swiss-Prot [16], SNPedia [25], COSMIC [34], OMIM [44], Clinvar [63], In-
SiGHT [78], dbSNP [93], MutDB [95], HGMD [99], HGVbaseG2P [104], PharmGKB [105],
BioMuta [115], etc. All these databases are manually curated by human experts. While
this manual curation ensures a high quality of the annotations, the manual extraction of
this type of information from the biomedical literature takes an enormous amount of time
and effort. The current rate with which new variants are published is simply too high for
any manual annotation process. As an additional challenge, despite the HGVS (Human
Genome Variation Society) standard recommendations for the description of the variants,
many variants are still reported in the literature in non-standard formats. A number of
automatic mutation indexing tools have been developed. Such tools process biomedical
literature and produce a list of mutations that appear in these papers. These include
MutationMiner [9], MutationFinder [23], EMU [29], MuteXt [49], Mutation Grab [67],
MEMA [82], etc. The most recent such tool, tmVar 2.0 [114] extracts variants from an
article and normalizes them to their unique dbSNP identifiers. The next step is to develop
software tools to extract variants-disease associations from the biomedical literature. Sev-
eral methods have been proposed for this purpose such as OSIRIS [17], MuGeX [32],
EnzyMiner [118], the methods proposed by Singhal et al. [96, 97], etc. All these meth-
ods have been applied to only the title and the abstract section of biomedical articles.
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However, a comprehensive study showed that a significant number of genetic variants are
only included in the full text and the supplementary materials of the articles [55]. These
will be missed if the variants are only extracted from titles and abstracts. Doughty et
al. [29] also proposed a tool named EMU for extracting the disease-associated mutations
from biomedical literature. Although this tool automatically extracts the mutations and
their corresponding genes from an article, it still requires human curation to discover the
mutation-disease associations.
Here we propose an autoMated pipeline for inferring vAriant-driven Gene PanEls from
the full-length biomedical Literature (MAGPEL) [89]. As the first step, the proposed
framework employs word cloud analysis to identify the variant-relevant articles. The
variant-gene-disease associations are then extracted from these articles. An evidence-
based variant-driven gene panel is then generated based on the mined triplet informa-
tion. A comprehensive validation procedure illustrates the capabilities of the proposed
framework. We validate the proposed variant-driven gene panel by showing their abilities
to predict the patients’ clinical conditions (healthy vs. disease) on multiple independent
validation datasets.
This document is organized as follows. In chapter 2, we first present a survey on the
current publicly available databases and resources for disease-associated variants. Then,
we provide an overview of the existing variant indexing tools that are able to extract vari-
ant entities from biomedical text. Chapter 3 focuses on our proposed automated pipeline
for extracting variants from full-length biomedical literature. The detailed explanation of
each step of the proposed pipeline and also the proposed validation analysis are presented
in this chapter. Chapter 4 presents the results and the discussion section is provided in
3
chapter 5. Finally, the conclusion and future work are discussed in chapter 6.
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CHAPTER 2 BACKGROUND AND RELATED WORK
A genetic variant refers to the presence of alterations in the DNA sequences among
individuals within a population. The disease-associated variants and the genetic poly-
morphisms (not disease-associated variants) are the two main categories of the genetic
variants based on their frequencies within a population. Single-nucleotide polymorphism
(SNP) is the most common type of polymorphism that occurs when one single nucleotide
is replaced with another nucleotide. A disease-associated variant on the other hand refers
to the rare type of variant that increases the risk of developing diseases. There are sev-
eral forms of genetic variants depending on the changes in the reference sequence such as
insertions, deletions, duplications, etc [101]. The detailed explanations and examples for
each type of variants described on both the DNA level and the protein level are provided
in Tables 1 and 2, respectively.
Table 1: Different types of variants described at the DNA level based on HGVS (Hu-
man Genome Variation Society) standard recommendations (https://varnomen.hgvs.
org/recommendations/DNA/).






Insertion A sequence change when one or multiple nucleotides are
inserted.
c.104insT 104 NA T
Deletion A sequence change when one or multiple nucleotides are deleted. c.104delT 104 T NA
Substitution A sequence change when one nucleotide is replaced with another
nucleotide.
c.435C>G 435 C G
Duplication A sequence change when copy of one or multiple nucleotides are
inserted.
c.64_65dupTT 64_65 NA TT
Deletion-insertion A sequence change when one or multiple nucleotides are
replaced by one or multiple other nucleotides.
c.145_147delinsTGG 145_147 NA TGG
Inversion A sequence change when multiple nucleotides are replaced by
the reverse complement of the original sequence.
c.5657_5660inv 5657_5660 TCAG CTGA
Conversion A sequence change when multiple nucleotides are replaced by
multiple nucleotides copied from different positions in the
sequence.
c.732_749con818_835 732_749 NA NA
2.1 Current databases for disease-associated variants
With rapidly evolving sequencing technologies, the number of articles studying ge-
nomic variants and their associations with human diseases is dramatically increased [24,
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Table 2: Different types of variants described at the protein level based on HGVS (Hu-
man Genome Variation Society) standard recommendations (https://varnomen.hgvs.
org/recommendations/protein/).






Insertion A sequence change when one or multiple amino acids are
inserted.
p.His4_Gln5insAla 4_5 NA Ala
Deletion A sequence change when one or multiple amino acids are
deleted.
p.Trp4del 4 Trp NA
Substitution A sequence change when one amino acid is replaced with
another amino acid.
p.Trp24Cys 24 Trp Cys
Duplication A sequence change when copy of one or multiple amino acids are
inserted.
p.Ala3dup 3 NA Ala
Deletion-insertion A sequence change when one or multiple amino acids are
replaced by one or multiple other amino acids.
p.Cys28delinsTrpVal 28 NA TrpVal
Frame shift A sequence change because of translation shift into another
reading frame.
p.Arg97ProfsTer23 97 Arg Pro
124]. Publicly available databases such as SNPedia [25], Clinvar [63], dbSNP [93],
TopoSNP [100], etc. have been developed to aggregate and provide easy access to the
results of these studies. In this section, we provide an overview of such open-access repos-
itories designed specifically for the genomic variants (see Table 3).
Table 3: Summary of the current open-source warehouses providing information about
variants, genes, and disease phenotypes.
Database Description URL
dbSNP [93] Catalog of SNPs https://www.ncbi.nlm.nih.gov/snp/
PharmGKB [47] Catalog of human variations and drug responses https://www.pharmgkb.org/
Ensembl [50] Catalog of vertebrate genomes https://ensembl.org
TopoSNP [100] Catalog of SNPs http://sts.bioe.uic.edu/toposnp/
COSMIC [34] Catalog of cancer-associated somatic mutations https://cancer.sanger.ac.uk/cosmic
SNPedia [25] Catalog of disease-associated SNPs https://snpedia.com
SwissVar [119] Catalog of mutations present in UniProt https://swissvar.expasy.org
ICGC [123] Catalog of cancer-associated variants https://dcc.icgc.org
HGVbaseG2P [104] Catalog of disease-associated variants https://www.gwascentral.org
1000 Genomes [74] Catalog of human variations https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/
MoKCa [85] Catalog of cancer-associated mutations http://strubiol.icr.ac.uk/extra/mokca/
OMIM [3] Catalog of disease-associated mendelian mutations https://omim.org
Clinvar [63] Catalog of disease-associated variants https://www.ncbi.nlm.nih.gov/clinvar/
IntOGen-mutations [41] Catalog of cancer-associated mutations https://www.intogen.org
BioMuta [28, 115] Catalog of cancer-associated SNPs https://hive.biochemistry.gwu.edu/biomuta
CIViC [42] Catalog of cancer-associated variants https://civicdb.org/home
LitVar [2] Catalog of variants and associated genes, diseases and drugs https://www.ncbi.nlm.nih.gov/CBBresearch/Lu/Demo/LitVar/
Established by the National Center for Biotechnology Information (NCBI), dbSNP is
the largest database providing information for the identified single nucleotide variants
(SNPs) [93]. The latest version of dbSNP (build 154) which was released in April 2020
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contains over two billion submitted SNP and 729,491,867 reference SNP records. For each
SNP record, dbSNP provides a wide range of information described as follows:
• The clinical significance tab provides a list of diseases known to be associated with
the queried SNP derived from ClinVar [63].
• The frequency tab displays a table of the reference and the alternative allele frequen-
cies for the queried SNP obtained from biomedical articles.
• The aliases tab displays all the different HGVS entries such as DNA and protein level
HGVS format of the queried SNP.
• The submissions tab shows a list of variants originally were submitted to dbSNP and
now support the queried SNP.
• The history tab displays all the associated RefSNPs published in the previous dbSNP
versions.
• The publications tab displays all the PubMed articles that mention the queried SNP.
The Human Genome Variation database of Genotype to Phenotype (HGVbaseG2P) is
a website providing information for the identified SNPs and their related diseases [104].
For each SNP record, this database provides the general genomic information as well as
the corresponding hyperlinks to OMIM [3], SNPedia [25], and dbSNP [93] databases for
further information.
The disease-SNP association database named SNPedia [25] provides a summary of
the existing knowledge about the disease-associated SNPs through a user-friendly web-
based tool. For each queried SNP, in addition to the basic genomic information such
7
as chromosome number, position, alleles, etc. this database provides hyperlinks to the
external databases such as dbSNP [93], ClinGen [83], etc. The list of articles that have
cited the queried SNP is also available through SNPedia.
ClinVar [63] is one of the largest publicly available web-based tools for human genetic
variants. This database was launched in 2013 by the National Center for Biotechnology
Information, National Institutes of Health (NIH). The variants are submitted to ClinVar
by the research and clinical laboratories and expert groups. For each variant record, in
addition to the basic genomic properties, the corresponding ClinVar web page provides
the following information:
• The Conditions tab provides information and evidence regarding the diseases known
to be associated with the queried variant.
• The Gene(s) tab shows the region overview of the variant’s corresponding gene as
well as a hyperlink to the gene’s corresponding page in the OMIM [3] database.
Several databases have been designed and implemented specifically for cancer-associated
variants. These includes BioMuta [28, 115], COSMIC [34], CIViC [42] and ICGC [122].
The Catalogue Of Somatic Mutations In Cancer (COSMIC [34]) is the largest database
contains cancer-related somatic mutations. The two main resources feed into this database
are i) manually curation of the scientific literature and ii) the Cancer Genome Project
(CGP) at the Sanger Institute UK. For each mutation record, COSMIC provides the follow-
ing information:
• The Overview tab provides a summary of the general genomic properties of the
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queried mutation such as chromosome, position, reference, and alternative alleles
and the corresponding gene.
• The Tissue distribution tab shows the top 5 tissue types with the highest number of
identified mutated samples.
• The Samples tab displays all the available information for the mutated samples such
as tissue, histology, zygosity, and also reference articles.
• The Pathway affected tab shows a list of pathways known to be affected by the queried
mutation.
• The References tab shows a list of publications providing evidence and information
for the queried mutation.
The International Cancer Genome Consortium (ICGC) data portal [122] is an advanced
web-based tool providing comprehensive information for the mutations identified in sev-
eral major cancer types. This database is a collection of over 81 million cancer-associated
mutations collected from 86 different projects. For each mutation record, ICGC provides a
wide range of information such as:
• The Summary tab summarizes all the available information for the queried mutations
such as genomic properties, cancer distribution, etc.
• The Clinical evidence tab shows a table with all the available clinical studies related to
the queried mutation obtained from the Clinical Interpretation of Variants in Cancer
(CIViC) database [42].
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• The Protein tab shows the distribution of the identified mutations along with the
corresponding protein sequences.
• The Genome viewer tab provides the region overview of the corresponding gene.
BioMuta [28, 115] is another web-based tool designed specifically for cancer-associated
SNPs. This tool collects data from different resources such as UniProt [8], COSMIC [34],
IntOGen [41], ClinVar [63], TCGA [103] and ICGC [122]. BioMuta provides the list of the
most common variants identified for each cancer type. The general page layout provided
by BioMuta for a queried gene contains information for all the identified Nonsynonymous
single-nucleotide variations (nsSNVs) such as the genomic coordinates, the identified can-
cer types, and the supporting articles.
Clinical Interpretation of Variants in Cancer (CIViC [42]) is another open access re-
source for the cancer-associated variants. For each queried gene, this database provides
detailed information about all the identified cancer-related somatic mutations. These in-
clude the variant genomic coordinates and the corresponding hyperlinks to the external
databases such as COSMIC [34], ClinVar [63], and dbSNP [93].
Finally, PharmGKB [47] provides association information regarding human genetic
variations and drug responses. The main goal of this database is to integrate available
knowledge regarding human genetic variations and their effects on drug responses. For
each queried gene, this database summarizes all the genomic variants associated with the
queried gene, the drug it interacts with as well as hyperlinks to the corresponding evi-
dence, studies, and articles.
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2.2 Current automatic variant indexing tools
The current database curators are not able to keep track of all the new annotated vari-
ants because the current rate with which new variants are published is too high. In order
to keep up with the new variants being published in the literature, a number of automation
tools for indexing mutations from the biomedical text have been developed [53]. These
tools use different computational algorithms such as conditional random field (CRF), regu-
lar expressions (RegExp), machine learning, and graph theory to identify variant-genotype-
phenotype associations from biomedical literature. In the following, we review some of
these methods focusing on the underlying concept used, primary features, availability, and
key advantages (see Table 4).
Table 4: List of existing text-mining variant extraction methods based on the criteria re-
lated to the computational models and implementations.
Method Concept used Availability Language Year
VTag [73] Conditional random field N/A N/A 2004
MuteXt [49] Regular expressions Standalone Python 2004
MEMA [82] Regular expressions N/A N/A 2004
MutationMiner [9] Regular expressions N/A N/A 2006
YIP [119] Regular expressions N/A N/A 2007
MuGeX [32] Regular expressions N/A N/A 2007
Mutation GraB [67] Regular expressions N/A N/A 2007
MutationFinder [23] Regular expressions Standalone Python, Perl, Java 2007
EMU [29] Regular expressions Standalone Perl 2011
tmVar [112] Conditional random field Standalone Java 2013
tmVar 2.0 [114] Conditional random field Standalone Java 2017
A number of methods have been proposed for the variant entity extraction from text
using a machine learning technique named conditional random fields (CRF) [62]. The
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main characteristics of these methods are summarized in Table 5.
Table 5: Summary of the important characteristics of the reviewed conditional random
field (CRF) approaches for variant extraction from biomedical text.
Method Type of mutation Gene/protein identification Disease identification RSID normalization
VTag [73] Protein, DNA 7 7 3
tmVar [114] Protein, DNA, SNP 3 7 7
tmVar 2.0 [114] Protein, DNA, SNP 3 7 3
McDonald et al. [73] proposed an automated variant extraction tool named VTag in
2004. The proposed CRF-based method extracts the sequence variations mentioned in the
cancer-related articles and further maps them to their corresponding dbSNP identifiers. On
a corpus of 105 cancer-related abstracts, the method achieves 79% recall, 85% precision,
and 82% F-measure score.
Wei et al. [112] proposed another CRF-based model named tmVar to extract the men-
tioned variants from biomedical articles. The proposed model considers each component
of a variant entity as one label and the variant itself as a sequence of labels. For exam-
ple, tmVar retrieves each component of c.607_608insACA mutation separately (eg. “ins”
as the mutation type, “CAA” as the alternative sequence and “607_608” as the position).
Identification of a wide range of mutation types (DNA, protein, and SNP) is one of the key
advantages of tmVar. In 2017, the second version of this tool named tmVar 2.0 [114] was
proposed. This tool first extracts the variant entities using the same algorithm as tmVar
and further normalizes them to their unique dbSNP identifiers.
Several methods have been proposed to extract variants from biomedical literature
using the standard regular expressions algorithm (RegExp). Here, we review several of
these methods which are listed in Table 6.
Horn et al. [49] introduced MuteXt for extracting point mutations from biomedical
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Table 6: Summary of the important characteristics of the reviewed regular expressions
(RegExp) approaches for variant extraction from biomedical text.
Method Type of mutation Gene/protein identification Disease identification RSID normalization
MuteXt [49] Protein, DNA 3 7 7
MEMA [82] Protein, DNA 3 7 7
MutationMiner [9] Protein 7 7 7
MuGeX [32] Protein 3 3 7
MutationFinder [23] Protein 7 7 7
Mutation GraB [67] Protein 3 7 7
EMU [29] Protein, DNA 3 7 7
literature in 2004. MuteXt uses regular expressions (RegExp) with a pattern starts with
one amino acid that can be one- or three-letter term, followed by a number, and ends
with another amino acid followed by the format of the first one (e.g. G12D or Gly12Asp).
MuteXt is also able to extract protein names and species names from an article. The
identified mutation-protein pairs are then validated in two different ways: i) sequence
filtering and ii) distance filtering. The sequence filtering checks whether the reference
amino acid in the mutation position is matched with the amino acid in the corresponding
protein sequence. The distance filtering refers to the co-occurrence of the mutation, the
protein name, and the organism type in the text. The pairs with the shortest distance (word
counts) are considered as relevant. One limitation of MuteXt is that it is only trained to
retrieve mutations for GPCR and NR protein superfamilies.
MEMA, proposed by Rebholz et al. [82], is another regular expression (RegExp) based
mutation extraction tool that was only applied to the Medline abstracts. The proposed
method has three main steps: i) gene name identification, ii) mutation identification and
iii) disambiguation module. MEMA uses regular expression patterns for both gene and
mutation identification. For gene identification, the method simply searches for any gene
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name that matches with the list of genes obtained from the Human Genome Organization
(HUGO) gene database [79]. A set of 30 different patterns is used for the mutation iden-
tification. These include Arg506 to Gln, Ile15 to Thr15, 1166 A/C, C282Y, etc. Then, for
each identified mutation, the method follows a set of certain rules in order to identify the
corresponding gene:
1. If there is only one gene mentioned in the abstract, that gene would be considered
as the corresponding gene.
2. If the abstract contains multiple genes, the corresponding gene would be the one
mentioned in the same sentence as the mutation.
3. If there is more than one gene in the same sentence as the mutation, then the closest
mentioned gene (word counts) to the mutation would be considered as the corre-
sponding gene.
On a sample of 100 abstracts, MEMA achieves 67% recall, and 96% precision rate on the
mutation extraction, and 35% recall, and precision of 93% on the mutation–gene pairs
identification.
Erdogmus et al. [32] proposed MuGeX (Mutation Gene eXtractor) for mutation identi-
fication from the Medline abstracts. MuGeX uses a set of 20 different patterns for mutation
extraction such as G12D, Gly-12-Asp, Gly12 to Asp, Substitution of Glycine for Aspartic Acid
at position 12, etc. On a set 231 Medline abstracts the MuGeX mutation detection method
achieves 85.9% and 95.9% recall and precision, respectively. For the mutation–gene pairs
identification, the estimated recall, and precision is 91.3% and 88.9%, respectively. One
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drawback of this method is its inability to identify correct mutation-gene pairs when mul-
tiple mutations and genes mentioned in the text.
MutationFinder is another mutation extraction tool proposed by Caporaso et al. [23]
in 2007. The proposed method uses a modified version of the regular expression method
proposed by Erdogmus et al. [32]. These modifications include the following six new rules:
• The numeric position of the one-letter abbreviations mutation format should be
greater than a certain number.
• The one-letter allele of the mutation should be presented in the upper-case format.
• The reference and alternative alleles should not be the same.
• Unlike MuteXt [49], the proposed method is able to identify mutations with the non-
alphanumeric characters as well.
• MutationFinder is also able to identify mutations described in the human natural
language in addition to the abbreviated formatted mutations (e.g. Substitution of
Glycine for Aspartic Acid at position 12).
• The regular expression patterns are applied to each sentence separately.
Overall, MutationFinder had better performance (both recall and precision) compared to
MuteXt [49].
Lee et al. [67] proposed Mutation Graph Bigram (Mutation GraB) method for extracting
point mutations from biomedical literature. Similar to the previous methods in this cat-
egory, mutations and gene names are identified using the pre-defined regular expression
15
patterns. As the next step, the proposed method uses the graph-based bigram traversal
method to associate an identified mutation with a corresponding protein. In particular, for
each mutation entity, the method searches for the corresponding gene using the shortest
path distance algorithm. The identified mutation-protein pairs are then verified based on
the Swiss-Prot [16] database.
In 2010, Doughty et al. [29] introduced EMU, a semi-automated method for mutation-
genotype-phenotype identification from biomedical literature. The proposed method fol-
lows the same regular expression patterns proposed by Garten et al. [39] for the mutation
identification. EMU uses the HUman Genome Organization (HUGO) gene database [79]
as a dictionary containing the list of human genes to extract any gene names or their syn-
onyms from a text. Same as MuteXt [49], EMU also uses sequence filtering to validate the
extracted mutation-gene pairs.
Singhal et al. [96] implemented a machine-learning-based method to extract and iden-
tify the disease-related mutations from biomedical literature. The proposed method uses
tmVar [112] and DNorm [64] to extract mutation and disease entities, respectively. For a
target disease, the proposed method uses the following 6 different features to determine
whether the identified mutation G from an input article is related to the target disease D.
1. The number of times the target disease D is mentioned as the closest (based on word
counts) disease to the identified mutation G.
2. The number of times the target disease D is mentioned in the input article.
3. The number of times the next most frequently mentioned disease other than D is
mentioned in the input article.
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4. Whether the target disease D and the mutation G are mentioned in the same sentence
in the input article (binary score).
5. The sentiment score of the text between the mutation G and its nearest mention of
the target disease D.
6. The subjectivity of the sentiment score was calculated in step 5.
The authors used two benchmark datasets provided by EMU [29] as the training datasets.
As the next step, they used Weka3.6 tool [43] to build a machine learning classifier based
on the training datasets and the developed features set. The results showed the outperfor-
mance of the proposed method compared to EMU [29].
In another work, Singhal et al. [97] proposed an automatic framework for extracting
mutation-genotype-phenotype triplet associations from biomedical literature. The main
steps of the proposed work can be summarized as follows:
1. Disease, gene, and mutation identification from an input article using DNorm [64],
GNormPlus [113], and tmVar [112], respectively.
2. Disease-mutation association identification using their previous proposed method [96].
3. Gene-mutation association identification using PubMed Rank, Bing Rank, and se-
quence filtering methods. In particular, for an identified gene G and an identified
mutation M, these scores are calculated as follows:
• PubMed Rank: the frequency of appearances of the gene G in the abstract sec-
tion of the articles that are known to be related to the mutation M.
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• Bing Rank: the frequency of appearances of the gene G in the top 20 Bing search
results when searching for the mutation M.
• Sequence filtering: similar to the validation process proposed by Doughty et
al. [29], the sequence filtering process checks whether the reference amino acid
in the mutation position is matched with the amino acid in the associated gene’s
sequence.
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CHAPTER 3 PROPOSED METHOD
In this thesis, we propose an automated framework to extract disease-associated vari-
ants from the full-length biomedical literature and design a variant-driven gene signature
for a given disease phenotype. The process of extracting variants from a full-length article
is challenging because any chemical formulae, figure numbers, etc. that are represented in
a “character-number-character” format could potentially be a variant [114]. One solution
to address this challenge is to mine only the variant-relevant articles. As the first step, the
proposed framework employs word cloud analysis to identify such articles. The variant-
gene-disease associations are then extracted from these articles using the entity recogni-
tion tools. An evidence-based variant-driven gene signature is then generated based on
the mined triplet information. We use a comprehensive validation procedure to illustrate
the capabilities of the proposed framework. We compare the proposed panels with other
variant-driven gene panels obtained from Clinvar [63], Mastermind [40], and others from
the literature [29, 96], as well as with a panel identified with a classical differentially ex-
pressed genes (DEGs) approach. The proposed variant-driven gene signatures are then
validated by showing their abilities to predict the patients’ clinical conditions (healthy vs.
disease) on multiple independent validation datasets.
Figure 1 illustrates the proposed framework that consists of the following four major
modules: (1) obtain the full-length variant-relevant articles; (2) extract all the variant,
gene and disease entities from each input article; (3) identify the variant-gene, and the
variant-disease associations in each input article; (4) design a variant-driven gene panel
for a given phenotype. The detailed descriptions of each step are provided in the following
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sections.
Figure 1: Framework overview. Module (A) obtains all the publicly available full-length
articles from the PubMed Central (PMC) database. Then it uses the word cloud analysis
and generate a weighted list of variant-relevant keywords. The variant-relevant articles
are then selected based on the presence of this list in their full text (section 2.1). Module
(B) uses GNormPlus [113], tmVar 2.0 [114] and DNorm [64] tools to extract the gene,
variant, and disease phenotype entities, respectively (section 2.2). Module (C) extracts
the gene-variant associations from each input article (section 2.3). This module also uses
a set of features to discover the disease-variant associations (section 2.4). Module (D)
generates a panel consists of the variant-gene-disease associations.
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3.1 Variant-relevant input corpus
The input of the proposed framework consists of 3,322,746 full-length articles down-
loaded from the PMC database in January 2020. The variant indexing procedure from a
full-length article is challenging because any chemical formulae, figure numbers, etc. that
are represented in “Character-Number-Character” format could be identified as a vari-
ant [114]. One solution to address this challenge is to mine only the variant-relevant arti-
cles. We compare the performances of two different approaches for detecting the variant-
relevant articles. The first approach considers only the articles that mention any disease
or gene or any of their synonyms in the title and abstract sections [40]. In the second
approach, we employ the word cloud analysis and generate a weighted list of variant-
relevant keywords. In particular, we first generate a weighted list of words (referred to as
variant-relevant keywords) that appear frequently in the full-body text of 10,000 random
articles with at least one mentioned variant (using tmVar 2.0). Subsequently, an article is
considered to be relevant to variants if at least 10% of these keywords appear in the full-
body of the article. We apply both approaches on a new set of 10,000 random full-length
articles. Figure 2 shows the identified variant overlaps and differences between the two
approaches.
The number of papers with at least one mentioned variant overlapped between the
two approaches is 836 and the number of overlapped variants is 5,476. The number of
variants that are only found by the first approach is 284 from 91 papers, in which a manual
validation process revealed that 97% of them are false positive (extracted entity is not a
variant and it is wrongly identified as a variant.). The number of variants that are only
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Figure 2: Among the 10,000 random articles, the articles with at least one mentioned
mutation are selected (using tmVar 2.0). We compare the performances of two different
approaches for detecting the variant-relevant articles. The first approach identifies articles
that mention any disease or gene or any of their synonym in their titles and abstracts [40].
In the second approach, we only search for the articles that mention the variant-relevant
keywords in their full-body text. The variant-relevant keywords list is a weighted list
of the words that appear frequently in a set of 10,000 random articles with at least one
mentioned variants (using tmVar 2.0). Subsequently, an article is considered to be relevant
to variants if at least 10% of these variant-relevant keywords are appearing in the full-body
text. The number of variants that are found in the articles selected by the first approach and
the second approach is 5,760 and 6,087, respectively. The number of variants identified
by both approaches is 5,476. The number of variants that are only found by the first
approach is 284, of which 97% are false positive (extracted entity is not a variant and it is
wrongly identified as a variant.). The number of variants that are only found by the second
approach is 611, of which only 10% are false positive. These results show that the second
approach which is based on the variant-relevant keywords outperforms the first approach.
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found by the second approach is 611 from 122 papers, in which only 10% of them are
false positive. The manual validation of the extracted variants to listed in Appendix Table
33. These results show that the second approach which is based on the variant-relevant
keywords outperforms the first approach. This leads us to the conclusion that the second
approach performs better in terms of the ability to index the variant-relevant articles. This
approach results in a list of 1,274,775 full-length articles that contain genomic variants.
3.2 Extract the variant, gene and disease entities
We use the publicly available and well-known entity recognition tools to extract the
variant, gene, and disease phenotype from each input article. In particular, we use GNorm-
Plus [113] to identify the appropriate genes. The tmVar 2.0 [114] is the tool we employ for
extracting the variants and normalizing those which are included in dbSNP to their unique
identifiers (dbSNP RSIDs). We use DNorm [64] to identify all the disease phenotypes
mentioned in an article.
3.3 Extract the variant-gene associations
Once a variant is extracted from an input article, we follow the steps provided by Wei et
al. [114] to find the associated gene. Then, we map each retrieved variant-gene pair to
the corresponding genomic coordinates (chromosome number, position, reference and al-
ternative alleles) using the Variant Recoder [50] tool. Variant Recoder provides translation
between the different formats of a variant. This tool supports HGVS annotations as well
as dbSNP, Clinvar [63], and PharmGKB [47]. We eliminate the variant-gene associations
with no matched genomic coordinates (referred to as false positive pairs).
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3.4 Extract the variant-disease associations
We use a set of features to capture the variant-disease associations from an input article
adapted from tmVar [96]. Let C = {V,D1, D2, ..., Dk} be a collection of appearances of the
variant V and the closest (based on the word counts) mentioned diseases in an article,
where k is the number of times this variant is mentioned in that article. The disease
association score is calculated for each appearance of variant V and the closest mentioned
disease Di, where 1≤i≤k. This score is the summation of the following set of scores:
• The Same Sentence Occurrence (SSO) is a binary score which is 1 when the variant V
and the disease Di are mentioned in the same sentence and 0 otherwise.
• The Same Paragraph Occurrence (SPO) is a binary score which is 1 when the vari-
ant V and the disease Di are mentioned in the same paragraph and 0 otherwise.
• The sentiment score (SS) calculates the polarity sentiment value for the text men-
tioned between the variant V and the disease Di. We use the R package “senti-
mentr” [86] for this analysis.
The variant V is considered to be associated with disease Di that has the highest disease
association score.
We also performed an experiment to compare the performance of the proposed scor-
ing method for extracting the variant-disease associations with the simple sentence co-
occurrence scoring method. In this experiment, we used two manually curated benchmark
datasets provided by Doughty et al. [29]. These datasets contain variant-disease pairs
extracted from 29 and 129 PubMed articles for prostate cancer and breast cancer, respec-
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Table 7: Comparison of the proposed variant-disease association scoring method with the
baseline approach (Co-occurrence only) on the benchmark datasets. These datasets are
provided by Doughty et al. [29]. The proposed approach performs better compare to the
baseline approach.








F1 measure 0.88172 0.36559
tively. We used these datasets and reported the standard evaluation metrics (precision,
recall and F1-measure) for the proposed scoring approach compared to the sentence co-
occurrence scoring approach. As shown in Table 7, the proposed method outperforms the
baseline method which is only based on the sentence co-occurrence appearance of the
variant-disease pairs. The complete list of mined variant-disease pairs for this experience
is listed in Appendix Table 32.
3.5 Variant-driven gene panel design
In this step, we first generate a variant-gene-disease panel which includes all the asso-
ciations between the gene, variant, and disease entities extracted from the input corpus
(Module D in Figure 1). This panel includes 18,254 genes with 313,780 variants discov-
ered to be associated with 5,202 unique diseases. For a given disease, we then generate
the variant-driven gene panel which includes all the genes with at least one mentioned
variant discovered to be associated with the given disease.
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3.6 Validation method
In this section, we describe two experiments performed to assess the diagnostic value
of the proposed variant-driven gene panel.
In the first experiment, we use the genes present in the proposed panel to predict the
patients’ clinical condition (healthy vs. disease) from several independent patient cohorts.
The hypothesis is that a better gene panel will yield better classification results. For this
purpose, we use disease gene expression datasets and machine-learning classification tech-
niques. A disease gene expression dataset is a matrix in which the rows represent the mea-
sured genes and the columns represent the samples (healthy or disease individual). The
value in each cell is the expression level of a gene in a particular sample. We use cross-
validation method for this analysis. In particular, in each round of sampling, we use one
of the gene expression datasets as the training dataset and we use the rest as the testing
datasets. We use the genes present in the proposed variant-driven gene panel along with
their expression values from the training dataset to build a random forest classifier [20].
Then, we apply the trained classifier on each of the testing datasets in order to predict the
patients’ clinical outcomes. We use the area under the curve (AUC) of the receiver-operator
characteristic (ROC) to assess the performance of the classifier. We repeat this procedure
n times (where n is the number of available gene expression datasets). An average of the
AUCs is calculated over the n rounds of sampling. This procedure is used to compare the
diagnostic quality of the proposed gene panel with the current available variant-relevant
gene panels.
In the second experiment, we assess the relevance of the proposed gene panel to a given
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Figure 3: Validation framework overview. Module (A) identifies all the genes with at least
one variant discovered to be associated with the given disease by the proposed framework.
We refer to this list of genes as the proposed variant-driven gene panel. Module (B) first
analyzes several independent gene expression datasets studying the given phenotype. We
use a cross-validation method. In each round of sampling, we use one of the gene expres-
sion datasets as the training dataset and we use the rest as the testing datasets. We use
the expression values of the genes included in the proposed gene panel as the features to
build a classifier. Then, we apply the trained classifier on each of the testing datasets in
order to predict the patients’ clinical outcomes in each testing dataset. We use the area
under the curve (AUC) of the receiver-operator characteristic to assess the performance of
the classifier. We repeat this procedure n times (where n is the number of gene expression
datasets). An average of AUCs is calculated over the n rounds of sampling. This procedure
is used to compare the diagnostic quality of the proposed variant-driven gene panel with
the current available variant-relevant gene panels.
27
disease based on the rank of the target pathway when an enrichment pathway analysis is
performed. A “target pathway” refers to the pathway that was created to explain the mech-
anism of the given disease (e.g. the acute myeloid leukemia KEGG pathway (hsa05221) is
the target pathway for acute myeloid leukemia).
A signaling pathway refers to a graph in which nodes represent genes/proteins, and
edges represent existing interactions between such genes or proteins. In general, the main
goal of the pathway analysis methods is the correct identification of the pathways that are
significantly impacted when comparing two phenotypes (e.g. healthy vs. disease) [30, 58].
Many pathway analysis methods have been proposed [75, 76, 58]. A very recent exten-
sive benchmarking of the existing pathway analysis methods are provided by Nguyen et
al. [77].
In this thesis, we use the enrichment pathway analysis method called over-representation
analysis (ORA) [57]. The goal of this method is to find the pathways that are enriched
within a list of genes. In particular, this method calculates the probability of finding a cen-
ter number of gene overlaps between the proposed gene panel and the presented genes in











In this equation, N is the total number of genes in the genome that have been anno-
tated, n is the total number of genes in the proposed gene panel, k is the total number
of gene overlaps between the proposed gene panel and the pathway P, and M is the total
number of genes included in the pathway P.
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These probability values are calculated for all pathways. Subsequently, they should be
adjusted for multiple comparisons with an approach such as the false discovery rate correc-
tion (FDR) [13, 14]. For each pathway, if the FDR-corrected p-value is less than a certain
threshold (usually less than 0.05), then the pathway is considered to be significantly in-
volved in the experiment. The list of significant pathways is then ranked from the one with
the lowest FDR-corrected p-value (most significant) to the one with the highest p-value
(least significant). For this analysis, we use the R package “clusterProfiler v3.12.0” [120].
The expectation here is that a gene panel that is relevant to the given disease would rank
the target pathway at the very top of the ranked list of pathways. This validation method
was widely adopted by others, such as [5, 51, 69, 71, 75, 76, 77, 91, 102]. We also provide
the top 10 significantly enriched pathways and the references explaining the association
of the respective pathways to the disease case study for each gene panel.
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CHAPTER 4 RESULTS
As representative examples, we present the results for acute myeloid leukemia (AML),
breast cancer, and prostate cancer. The resulted gene panel proposed for each case study
is included in the Appendix. All the gene expression datasets used in this manuscript for
the classification analysis are obtained from GEO [12].
For each disease case study, we also calculate the percentage of the genes in the pro-
posed gene panel that overlap with the genes in each gene expression dataset. We per-
formed the following experiment as a quality check to ensure that the majority of the
genes in the proposed gene panel are contributing to the validation analysis. In order to
do this, we calculated the percentage of the genes in the proposed gene panel that overlap
with the genes in the training dataset as follows:
In this equation, N represents the genes in the proposed gene panel and M represents
the genes in the training gene expression dataset. For each case study, the average of this
percentage across all the gene expression datasets is more than 80% (Tables 8 to 10).
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Table 8: The percentage of the genes in each AML gene panel that overlap with the genes
in each GEO gene expression dataset.
Dataset MAGPEL (proposed) Mastermind Clinvar [63] Singhal et al. [97]
GSE15061 96.94 97.44 88.68 90.24
GSE17054 96.51 97.12 88.68 90.24
GSE34577 97.38 98.4 88.68 90.24
GSE35008 92.58 95.53 86.79 87.8
GSE37307 90.39 95.21 79.25 84.15
GSE42140 96.51 97.12 88.68 90.24
GSE9476 90.39 95.21 79.25 84.15
GSE982 90.39 95.21 79.25 84.15
Average 93.88 96.40 84.90 87.65
Table 9: The percentage of the genes in each prostate cancer gene panel that overlap with
the genes in each GEO gene expression dataset.
Dataset MAGPEL (proposed) EMU [29] Clinvar [63] Singhal et al. [97]
GSE12348 86.28 100.00 68.01 85.87
GSE17906 97.18 100.00 89.08 94.35
GSE17951 97.18 100.00 89.08 94.35
GSE32448 97.18 100.00 89.08 94.35
GSE46602 97.18 100.00 89.08 94.35
GSE55945 97.18 100.00 89.08 94.35
GSE68882 75.56 82.35 50.00 72.44
GSE6956 86.28 100.00 68.01 85.87
GSE70768 98.31 100.00 94.44 94.35
Average 92.48 98.04 80.65 90.03
Table 10: The percentage of the genes in each breast cancer gene panel that overlap with
the genes in each GEO gene expression dataset.
Dataset MAGPEL (proposed) EMU [29] Clinvar [63] Singhal et al. [97]
GSE10780 97.66 100.00 85.64 86.90
GSE10810 75.05 72.73 50.21 61.90
GSE20086 97.66 100.00 85.64 86.90
GSE29431 97.66 100.00 85.64 86.90
GSE36295 94.74 95.45 85.47 85.69
GSE42568 97.66 100.00 85.64 86.90
GSE54002 97.66 100.00 85.64 86.90
GSE61304 97.66 100.00 85.64 86.90
GSE86374 94.74 95.45 85.47 85.69
GSE8977 92.01 95.45 73.83 79.44
Average 94.25 95.91 80.88 83.41
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4.1 Acute myeloid leukemia
First, we extract all the genes with at least one mentioned variant discovered to be as-
sociated with AML by the proposed framework (Table 29). The top 10 genes that have the
highest number of variants are TP53, FLT3, KIT, DNMT3A, IDH1, COX8A, RUNX1, TYMS,
NPM1, and SLC29A1. These genes play significant roles in the underlying mechanisms of
AML. For instance, Kadia et al. [56] demonstrated that AML patients with TP53 alterations
have a lower response rate to intensive chemotherapy and therefore have an inferior sur-
vival rate. FLT3 and C-KIT are known to be associated with poor AML prognosis discovered
by Pratz et al. [80] and Yang et al. [117], respectively. Ley et al. [68] investigated the role
of DNMT3A and found that there is a direct link between the presence of mutations in this
gene and the intermediate risk of AML. Chaturvedi et al. [27] also reported the therapeu-
tic role of mutant IDH1 in AML. Gaidzik et al. [37] have shown that therapy-resistance
and inferior outcomes are the main genetic characteristics of AML patients with RUNX1
mutations. The presence of mutations in TYMS and NPM1 is also discovered in AML pa-
tients [38, 70]. SLC29A1 mutations are found to be associated with poor therapy outcome
in AML patients [59].
We assess the utility of the proposed gene panel on independent gene expression
datasets studying AML obtained from GEO [12]. Dataset summaries are described in Ta-
ble 11.
The other variant-driven gene panels which are available for AML are obtained from
Clinvar [63], Mastermind [40], and the panel proposed by Singhal et al. [97] Clinvar
is a repository for mutations and their associated disease phenotypes which are man-
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GSE15061 Gene array prediction of AML transformation in MDS 202 69
GSE17054 Dysregulated gene expression networks in human acute
myelogenous leukemia stem cells
9 4
GSE2191 pediatric AML and normal bone marrow 54 4
GSE34577 Routine use of microarray-based gene expression profiling to
identify patients with low cytogenetic risk acute myeloid
leukemia
21 8
GSE35008 Expression data from human hematopoietic stem and progenitor
compartments from patients with acute myeloid leukemia with
normal karyotype and healthy controls
12 16
GSE37307 Aberrant expressed genes in AML 30 19
GSE42140 Gene expression in signaling subsets of AML blasts induced by
G-CSF
33 7
GSE9476 Abnormal expression changes in AML 26 38
GSE982 Gene Expression-Based High Throughput Screening: HL-60 Cell
Treatment with Candidate Compounds
9 6
ually curated from the biomedical literature. The Mastermind search engine provides
literature-based variant-genotype-phenotype association information. We also include the
results when using only the differentially expressed genes (FDR-corrected p-value<0.05
and | log2(fold change)|>=1.5) as a gene panel. Figure 4 illustrates the performance com-
parison of these gene panels. The results show that the classification based on the proposed
gene panel achieves the best result (the highest median AUC value) and outperforms the
classification based on all the other published panels.
The results for the pathway enrichment analysis are summarized in Table 12. The
proposed gene panel has better performance than the other available panels and ranked
the AML target pathway as the top-ranked pathway. The top 10 significantly enriched
pathways and the references explaining the association of the respective pathways to AML
for each gene panel are summarized in (Tables 13 to 16).
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Figure 4: The diagnostic performances of the random forest classifier based on five dif-
ferent gene panels. In this figure, the proposed panel (blue panel) performs better than
the ones obtained from Clinvar (red panel), Mastermind [40] (purple panel), the panel
proposed by Singhal et al. [97] (green panel), and the differentially expressed genes (FDR-
corrected p-value<0.05 and | log2(fold change)|>=1.5) (DEGs) (olive-tone panel) in terms
of the ability to distinguish between healthy volunteer and the AML patients. In this fig-
ure, the black dot inside each box plot represents the mean AUC value and the dashed line
represents the highest median AUC value.
Table 12: The results of the pathway enrichment analysis based on four different gene
panels for AML. The comparison is based on the rank of the acute myeloid leukemia KEGG
pathway (hsa05221). The proposed panel performs better in terms of the ability to highly
rank the target pathway.
Panel Number of genes Rank of target pathway p-value (FDR)
MAGPEL (proposed) 229 1 1.57E-15
Clinvar [63] 53 2 8.36E-07
Singhal et al. [97] 76 3 1.62E-14
Mastermind [40] 313 9 5.50E-26
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Table 13: The top 10 significantly enriched pathways identified by the enrichment pathway
analysis based on the proposed gene panel (MAGPEL) for AML case study. Rows with green
background indicate the target pathway for AML. Rows with blue background indicate
pathways for which we found indication of their association to AML.
Rank Pathway name p-value (FDR)
1 Acute myeloid leukemia 1.57E-15
2 PI3K-Akt signaling pathway [1, 61] 2.42E-11
3 Transcriptional misregulation in cancer [88] 1.44E-10
4 Prostate cancer 1.44E-10
5 ErbB signaling pathway [109] 1.44E-10
6 Chronic myeloid leukemia [90] 2.26E-10
7 PD-L1 expression and PD-1 checkpoint pathway in cancer 2.26E-10
8 JAK-STAT signaling pathway [33] 1.26E-09
9 Hepatitis B 1.26E-09
10 EGFR tyrosine kinase inhibitor resistance 3.18E-09
Table 14: The top 10 significantly enriched pathways identified by the enrichment path-
way analysis based on the Clinvar [63] gene panel for AML case study. Rows with green
background indicate the target pathway for AML. Rows with blue background indicate
pathways for which we found indication of their association to AML.
Rank Pathway name p-value (FDR)
1 PI3K-Akt signaling pathway [1] 2.53E-07
2 Acute myeloid leukemia 8.36E-07
3 Central carbon metabolism in cancer [18] 8.36E-07
4 PD-L1 expression and PD-1 checkpoint pathway in cancer 3.76E-06
5 Thyroid cancer 1.54E-05
6 Bladder cancer 1.89E-05
7 Chronic myeloid leukemia [90] 1.89E-05
8 EGFR tyrosine kinase inhibitor resistance 2.08E-05
9 Endometrial cancer 8.42E-05
10 Non-small cell lung cancer 0.00014
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Table 15: The top 10 significantly enriched pathways identified by the enrichment pathway
analysis based on the Singhal et al. [97] gene panel for AML case study. Rows with green
background indicate the target pathway for AML. Rows with blue background indicate
pathways for which we found indication of their association to AML.
Rank Pathway name p-value (FDR)
1 JAK-STAT signaling pathway [33] 2.13E-17
2 Chronic myeloid leukemia [90] 4.70E-15
3 Acute myeloid leukemia 1.62E-14
4 Human T-cell leukemia virus 1 infection 1.44E-10
5 Transcriptional misregulation in cancer [88] 1.53E-09
6 Hepatitis B 2.39E-09
7 PI3K-Akt signaling pathway [1] 2.39E-09
8 Non-small cell lung cancer 4.48E-09
9 Central carbon metabolism in cancer [18] 6.29E-09
10 Pancreatic cancer 1.51E-08
Table 16: The top 10 significantly enriched pathways identified by the enrichment pathway
analysis based on the Mastermind [40] gene panel for AML case study. Rows with green
background indicate the target pathway for AML. Rows with blue background indicate
pathways for which we found indication of their association to AML.
Rank Pathway name p-value (FDR)
1 Hematopoietic cell lineage 6.98E-37
2 JAK-STAT signaling pathway [33] 1.11E-34
3 PI3K-Akt signaling pathway [1] 6.78E-34
4 Transcriptional misregulation in cancer[88] 1.97E-30
5 Hepatitis B 2.60E-30
6 Human T-cell leukemia virus 1 infection 8.14E-30
7 Epstein-Barr virus infection 7.66E-29
8 Kaposi sarcoma-associated herpesvirus infection 1.53E-27
9 Acute myeloid leukemia 5.50E-26
10 Prostate cancer 6.83E-26
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4.2 Prostate cancer
In this case study, we discover 532 genes with variants associated with prostate can-
cer (Table 30). The proposed prostate cancer variant-driven gene panel contains several
genes known to be involved in prostate cancer development and progression. For instance,
the androgen receptor (AR) plays important role in prostate cancer cell proliferation as
demonstrated by Balk et al. [10] The mutated BRCA2, TP53, KLK3, and RNASEL genes are
directly associated with the risk of developing prostate cancer [108, 31, 60, 26]. SPOP is
the most frequent mutated gene in primary prostate cancer [11, 19].
The gene expression dataset summaries are described in the Table 17.




GSE12348 Prostate cancer cell lines and normal prostate epithelial and
stromal cells in primary culture
6 3
GSE17906 Gene expression down-regulation in prostate tumor-associated
stromal cells involves organ-specific genes
10 10
GSE17951 Gene expression analysis of prostate cancer samples using
Affymetrix U133Plus2 array
68 13
GSE32448 CPDR tumor-benign 80 genechip dataset 40 40
GSE46602 Expression data from prostate cancer and benign prostate glands 36 14
GSE55945 Gene expression profiling of prostate benign and malignant
tissue
13 8
GSE68882 Comprehensive gene expression analysis of prostate cancer
reveals distinct transcriptional programs associated with
metastatic disease
23 3
GSE6956 Tumor immunobiological differences in prostate cancer between
african-american and european-american men
69 18
GSE70768 Prostate cancer stratification using molecular profiles 125 74
The classification results also demonstrate that the proposed gene panel outperforms
the other available gene panels [63, 97, 29] in terms of the ability to predict the patients’
clinical outcome on several independent validation cohorts (Figure 5).
The results for the pathway enrichment analysis are summarized in Table 18. The
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Figure 5: The diagnostic performances of the random forest classifier based on five dif-
ferent gene panels. In this figure, the proposed panel (blue panel) performs better than
the ones obtained from Clinvar (red panel), the panels proposed by Singhal et al. [97]
(purple panel), EMU [29] (green panel), and also the differentially expressed genes (FDR-
corrected p-value<0.05 and | log2(fold change)|>=1.5) (DEGs) (olive-tone panel) in terms
of the ability to distinguish between healthy volunteer and the breast cancer patients. In
this figure, the black dot inside each box plot represents the mean AUC value and the
dashed line represents the highest median AUC value.
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top 10 significantly enriched pathways and the references explaining the association of
the respective pathways to prostate cancer for each gene panel are also summarized in
(Tables 19 to 22).
Table 18: The results of the enrichment pathway analysis based on different gene panels
obtained for prostate cancer. The comparison is based on the rank of the prostate cancer
KEGG pathway (hsa05215).
Panel Number of genes Rank of target pathway p-value (FDR)
MAGPEL (Proposed) 532 1 5.49E-28
Clinvar [63] 525 7 5.10E-05
Singhal et al. [97] 280 1 8.12E-12
EMU [29] 17 2 5.83E-07
Table 19: The top 10 significantly enriched pathways identified by the enrichment path-
way analysis based on the proposed gene panel (MAGPEL) for prostate cancer case study.
Rows with green background indicate the target pathway for prostate cancer. Rows with
blue background indicate pathways for which we found indication of their association to
prostate cancer.
Rank Pathway name p-value (FDR)
1 Prostate cancer 5.49E-28
2 FoxO signaling pathway [92] 3.13E-25
3 Endocrine resistance 2.29E-21
4 Colorectal cancer 2.29E-21
5 Pancreatic cancer 3.54E-21
6 PI3K-Akt signaling pathway [94] 2.35E-20
7 AGE-RAGE signaling pathway in diabetic complications 4.05E-19
8 Endometrial cancer 3.96E-18
9 Chronic myeloid leukemia 6.04E-18
10 Bladder cancer 1.51E-17
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Table 20: The top 10 significantly enriched pathways identified by the enrichment path-
way analysis based on the Clinvar [63] for prostate cancer case study. Rows with green
background indicate the target pathway for prostate cancer. Rows with blue background
indicate pathways for which we found indication of their association to prostate cancer.
Rank Pathway name p-value (FDR)
1 Pancreatic cancer 1.93E-06
2 Endometrial cancer 1.96E-06
3 Melanoma 1.69E-05
4 Endocrine resistance 1.69E-05
5 Breast cancer 2.71E-05
6 Non-small cell lung cancer 2.74E-05
7 Prostate cancer 5.10E-05
8 Colorectal cancer 6.29E-05
9 Glioma 7.57E-05
10 Bladder cancer 8.38E-05
Table 21: The top 10 significantly enriched pathways identified by the enrichment path-
way analysis based on the EMU [29] for prostate cancer case study. Rows with green
background indicate the target pathway for prostate cancer. Rows with blue background
indicate pathways for which we found indication of their association to prostate cancer.
Rank Pathway name p-value (FDR)
1 Endometrial cancer 4.96E-08
2 Prostate cancer 5.83E-07
3 Gastric cancer 5.13E-06
4 Colorectal cancer 8.28E-06
5 Platinum drug resistance 0.00015237
6 Hepatocellular carcinoma 0.00015268
7 Thyroid cancer 0.00054001
8 Bladder cancer 0.00064535
9 Breast cancer 0.00133837
10 Hepatitis C 0.00147899
Table 22: The top 10 significantly enriched pathways identified by the enrichment pathway
analysis based on the Singhal et al. [97]for prostate cancer case study. Rows with green
background indicate the target pathway for prostate cancer. Rows with blue background
indicate pathways for which we found indication of their association to prostate cancer.
Rank Pathway name p-value (FDR)
1 Prostate cancer 8.12E-12
2 Hepatitis B 1.82E-08
3 Platinum drug resistance 2.85E-07
4 Bladder cancer 2.85E-07
5 FoxO signaling pathway [92] 3.12E-07
6 Steroid hormone biosynthesis 1.66E-06
7 Pancreatic cancer 1.95E-06
8 Transcriptional misregulation in cancer 1.95E-06
9 PI3K-Akt signaling pathway [94] 3.08E-06
10 Endometrial cancer 5.58E-06
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4.3 Breast cancer
The resulted panel for breast cancer includes 513 genes. This panel contains several
genes that are known to play crucial roles in the underlying mechanisms of breast cancer.
For instance, BRCA1, BRCA2, TP53, ESR1, PIK3CA, ERBB2, and PALB2 are among the
genes with a high number of variants associated to breast cancer. The mutations in BRCA1,
BRCA2, and TP53 are well-known to be associated with a high breast cancer risk [35, 111].
ESR1 mutations are involved in hormone-resistant metastatic breast cancer [87, 107, 48,
36, 54]. PIK3CA is an oncogene in breast cancer [22, 7, 98, 52] and ERBB2 is shown to be
up-regulated in several breast tumors [45, 110, 116, 84]. PALB2 is also reported as one of
the breast cancer susceptibility genes [81, 6, 106, 121].
The gene expression dataset summaries are described in Table 23.




GSE10780 Proliferative genes dominate malignancy-risk gene panel in
histologically-normal breast tissue
42 143
GSE10810 Gene expression panels in breast cancer distinguish phenotype
charact., histological subtypes, and tumor invasivness
31 27
GSE20086 Heterogeneity of gene expression in stromal fibroblasts of human
breast carcinomas and normal breast
6 6
GSE29431 Identifying breast cancer biomarkers 25 12
GSE36295 Transcriptomic analysis of breast cancer 45 5
GSE42568 Breast cancer gene expression analysis 67 17
GSE54002 Gene expression profiling of LCM captured breast cancer cells 417 16
GSE61304 Novel bio-marker discovery for stratification and prognosis of
breast cancer patients
56 4
GSE86374 Analysis of somatic DNA copy number alterations and frequency
of breast cancer intrinsic subtypes from Mexican women
50 36
GSE8977 Bone-marrow-derived mesenchymal stem cells promote breast
cancer metastasis
7 15
We compare our panels with several other previously proposed variant-driven breast
cancer gene panels as follows: i) Clinvar [63], ii) Singhal et al. [97], iii) Doughty et al. [29]
and iv) the classical DEGs. The classification results demonstrate that the gene panel
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proposed here performs better than the other gene panels in terms of the ability to predict
the patients’ clinical outcome on several independent validation datasets (Figure 6).
Figure 6: The diagnostic performances of the random forest classifier based on five differ-
ent gene panels. In this figure, the proposed panel (blue panel) performs better than the
ones obtained from Clinvar (red panel), the panels proposed by Singhal et al. [97] (purple
panel) and Doughty et al. [29] (green panel), and also the differentially expressed genes
(FDR-corrected p-value<0.05 and | log2(fold change)|>=1.5) (DEGs) (olive-tone panel) in
terms of the ability to distinguish between healthy volunteer and the breast cancer pa-
tients. In this figure, the black dot inside each box plot represents the mean AUC value
and the dashed line represents the highest median AUC value.
The results for the pathway enrichment analysis are summarized in Table 24. The top
10 significantly enriched pathways and the references explaining the association of the
respective pathways to breast cancer for each gene panel are summarized in (Tables 25
to 28).
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Table 24: The results of the enrichment pathway analysis based on different gene panels
obtained for breast cancer. The comparison is based on the rank of the breast cancer KEGG
pathway (hsa05224).
Panel Number of genes Rank of target pathway p-value (FDR)
MAGPEL (Proposed) 513 15 5.21E-16
Clinvar [63] 445 22 1.45E-01
Singhal et al. [97] 100 152 4.96E-15
EMU [29] 44 6 1.46E-09
Table 25: The top 10 significantly enriched pathways identified by the enrichment pathway
analysis based on the proposed gene panel (MAGPEL) for breast cancer case study. Rows
with green background indicate the target pathway for breast cancer. Rows with blue
background indicate pathways for which we found indication of their association to breast
cancer.
Rank Pathway name p-value (FDR)
1 Proteoglycans in cancer 2.54E-27
2 Pancreatic cancer 2.41E-24
3 ErbB signaling pathway [46] 1.14E-23
4 Colorectal cancer 1.41E-23
5 Endocrine resistance 2.51E-21
6 Chronic myeloid leukemia 3.95E-21
7 Endometrial cancer 1.67E-20
8 Hepatitis B 1.46E-18
9 Prostate cancer 1.57E-18
10 EGFR tyrosine kinase inhibitor resistance 1.94E-18
Table 26: The top 10 significantly enriched pathways identified by the enrichment pathway
analysis based on the Clinvar [63] gene panel for breast cancer case study. Rows with green
background indicate the target pathway for breast cancer. Rows with blue background
indicate pathways for which we found indication of their association to breast cancer.
Rank Pathway name p-value (FDR)
1 Herpes simplex virus 1 infection 2.67E-21
2 Taste transduction 0.000787
3 Natural killer cell mediated cytotoxicity [4] 0.000787
4 Antigen processing and presentation 0.00196105
5 Fanconi anemia pathway 0.00196105
6 B cell receptor signaling pathway 0.00317
7 Human papillomavirus infection 0.00691236
8 Graft-versus-host disease 0.00691236
9 Pancreatic secretion 0.02699356
10 Aldosterone-regulated sodium reabsorption 0.02707948
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Table 27: The top 10 significantly enriched pathways identified by the enrichment pathway
analysis based on the EMU [29] gene panel for breast cancer case study. Rows with green
background indicate the target pathway for breast cancer. Rows with blue background
indicate pathways for which we found indication of their association to breast cancer.
Rank Pathway name p-value (FDR)
1 Prostate cancer 8.68E-11
2 Endometrial cancer 3.85E-10
3 Homologous recombination [21] 6.27E-10
4 Melanoma 1.33E-09
5 Platinum drug resistance 1.33E-09
6 Breast cancer 1.46E-09
7 Hepatocellular carcinoma 5.35E-09
8 Bladder cancer 1.38E-08
9 Gastric cancer 2.44E-08
10 Glioma 2.74E-08
Table 28: The top 10 significantly enriched pathways identified by the enrichment pathway
analysis based on the Singhal et al. [97] gene panel for breast cancer case study. Rows
with green background indicate the target pathway for breast cancer. Rows with blue
background indicate pathways for which we found indication of their association to breast
cancer.
Rank Pathway name p-value (FDR)
1 Proteoglycans in cancer 1.01E-20
2 Colorectal cancer 2.49E-20
3 Pancreatic cancer 4.76E-20
4 Prostate cancer 7.23E-20
5 Chronic myeloid leukemia 4.46E-19
6 Gastric cancer 3.30E-18
7 ErbB signaling pathway [46] 1.22E-17
8 Hepatocellular carcinoma 2.89E-17
9 Endometrial cancer 6.50E-17
10 Endocrine resistance 6.76E-17
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CHAPTER 5 DISCUSSION
We investigate the novelty of our identified genes by checking their overlap with other
available variant-driven gene panels for AML (Figure 7). Although 58% of the proposed
genes are not included in the other panels, the classification and pathway analysis based on
these genes achieve the best results. The gene differences between the proposed panel and
Clinvar could arise from the fact that Clinvar is a manually curated database. In principle,
manual curation is expected to yield very accurate but possibly incomplete annotations,
which is consistent with the smaller number of genes included in the Clinvar panel. The
consideration of only the title and abstract of the articles for extracting the variants by
Singhal et al. [97], could be the reason for the gene differences between these two panels.
The corresponding figures for prostate cancer and breast cancer are shown in Figures 8
and Figures 9, respectively.
We also investigate the percentage of the identified AML-related variants which are
mentioned in the title and abstract sections of the articles and compared them with those
that are mentioned in the full body of the articles but not in the title and the abstract.
Figure 10 visualizes the variant overlaps and differences between these sections. As the
figure shows, about 89% of the variants mentioned in an article do not appear in the
title and the abstract section, which emphasizes the need to analyze the entire text of the
articles. This represents a significant limitation of the existing methods that use only the
title and abstract sections of an article. The Venn diagrams for prostate cancer and breast
cancer are shown in Figures 11, 12, respectively.
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Figure 7: An overview of the gene overlaps and differences between the variant-driven
gene panels. The proposed gene panel (MAGPEL) consists of 229 genes. The AML-related
gene panel obtained from Clinvar and Mastermind includes 53 and 313 genes, respectively,
and the one proposed by Singhal et al. [97] includes 76 genes.
Figure 8: An overview of the gene overlaps and differences between the variant-driven
gene panels for prostate cancer. The proposed gene panel (MAGPEL) consists of 532 genes.
The prostate cancer-related gene panel obtained from Clinvar and EMU includes 525 and
17 genes, respectively, and the one proposed by Singhal et al. [97] includes 280 genes.
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Figure 9: An overview of the gene overlaps and differences between the variant-driven
gene panels for breast cancer. The proposed gene panel (MAGPEL) consists of 513 genes.
The breast cancer-related gene panel obtained from Clinvar and EMU includes 2,354 and
44 genes, respectively, and the one proposed by Singhal et al. [97] includes 445 genes.
Figure 10: An overview of the overlap and differences between the variants mentioned in
the title and abstract sections of the articles (green) and those that appear in the full body
of the articles but not in the title and abstract section (gold) in AML case study.
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Figure 11: An overview of the overlap and differences between the variants mentioned in
the title and abstract sections of the articles (green) and those that appear in the full body
of the articles but not in the title and abstract section (gold) in prostate cancer case study.
Figure 12: An overview of the overlap and differences between the variants mentioned in
the title and abstract sections of the articles (green) and those that appear in the full body
of the articles but not in the title and abstract section (gold) in breast cancer case study.
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CHAPTER 6 CONCLUSION
6.1 Summary of contributions
The number of published articles describing the disease-related variants had a dramatic
rise because of the recent advance sequencing technologies. This highlights the pressing
need for the development of automated tools that are able to extract the variant-disease
associations from literature. The manual extraction of this type of information from the
biomedical literature takes an enormous amount of time and effort. Several automatic
variant indexing tools have been developed to assist this manual curation. Correctly re-
trieving the disease-associated variants from biomedical texts remains a challenge mainly
because of the complexity of the natural language processing and inconsistent use of stan-
dard recommendations for variant description.
Here, we present an automated framework to design an evidence-based variant-driven
gene signature for a given disease phenotype. The identification of the variant-relevant
articles using the word cloud analysis and the consideration of the full-length articles are
the main contributions of the proposed framework. We illustrate the diagnostic value
of the proposed gene signatures in capturing the mechanism involved in acute myeloid
leukemia (AML), breast cancer, and prostate cancer using 29 independent gene expression
datasets containing a total of 2,203 patients. We compare our signatures with several other
available gene signatures as follows: i) Clinvar [63], ii) Mastermind [40], iii) Singhal et
al. [97], iv) Doughty et al. [29] and v) the classical differentially expressed genes. The
results show that the signatures obtained by the proposed framework yield better results
than the other signatures currently available for these phenotypes.
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We believe the proposed framework has significant advantages since it could be used
to identify the gene biomarkers that describe the key biological phenomena for a given
disease. The proposed framework is expected to be of interest to researchers from the
computational biology and machine learning community.
6.2 Future work
In this thesis, we proposed an automated framework to extract the variant-gene-disease
associations from biomedical literature. Studies have been shown the role of genomic mu-
tations in improving the patient survival rate, personalizing medicine, and also reducing
the risks of different therapies and drug responses [72]. However, the same as variants,
this information is also buried in the scientific literature. Future work involves the identi-
fication and extraction of associations between genomic variants and drug responses from
literature. For this purpose, first, we will use tmChem [65] to extract any chemical and
drug names from biomedical text. Then, we will use a set of features to identify the as-
sociations between the mentioned mutations and drug responses. Similar to the method
proposed by Mahmood et al. [72], our main interest is to capture the association between
mutation existence and the drug responses and the treatment outcome. We will use a gold
standard benchmark dataset named BRONCO [66] to validate the extracted variant-drug
response associations. Lee et al. [66] generated BRONCO which contains associations
between variant, gene, disease, drug, and cell line entities extracted from 108 full-text
biomedical articles. We will use the BRONCO dataset and will report the standard evalua-
tion metrics (precision, recall, and F1 score) for the proposed framework.
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APPENDIX A
Table 29: The list of variant-driven genes obtained by the proposed framework for AML.
FLT3 ATM STAT3 CD38 GSK3A GSK3B STAT5B ERG RPS6KB1
PSMD5 GFI1 CD8A SAMHD1 U2AF1 BCR IDH1 RPS10 NPM1
IDH2 FBXW7 SKI SPI1 CSF3R CEBPA JAK2 MYB HCFC1
DNMT3A LUC7L2 ZNF672 GH1 ARHGAP35 MYBPC2 RUNX1 PGK2 TNS3
LYZL4 MPL LYPLA1 EZH2 KIT TP53 ASXL1 EDNRB MYD88
CD274 CDCA7L PRPF4B TRIB1 CYP3A5 EIF4EBP1 EIF4B WT1 EEF1A2
NUP98 CBFB CD34 GLI1 PDGFRA ABL1 ELANE PTPA GATA2
MYC MAPK8 TNFRSF11A PIP4K2A PTPN11 CDK6 PML PTMS ZNF221
FOSL2 INO80B MTHFR PPP2R1A ERBB2 CALR TET2 GATA1 ZNF274
PPP2R2A LYST NCR2 FTO ALKBH1 PIK3CA FOXP3 FANCB KIR2DL4
MTOR CD33 PLXNB1 STAT1 KMT2B SHH MAP2K7 NUP62 RUNX2
IPO9 NT5C2 CBL KMT2A ZBTB7A MDM2 DDX41 HDAC1 NRAS
EGFR CYP2C19 ADAR APOBEC3A RUNX1T1 TERT IL3 FOS SMARCA5
RLF GRM1 LRP11 CREB1 MAPT TAPBPL CDKN1B ETV6 NOD2
SMC1A NCOR1 MALT1 SF3B1 TYK2 SETD2 ASXL3 RUNX3 HHEX
CYR61 FYN ABCB1 BCOR SMYD2 TYMS COX8A FSTL4 KRAS
CYP1B1 MAF ABCG2 HLA-G ARID5B SLC29A1 HLA-C HPSE MIR204
IL17A UNG HDAC9 CTNNB1 JAK3 EIF4E NR3C1 CTD HOXA9
ERCC2 MARCO WRN NAPRT IL10 CRBN GSTP1 NAT2 HFE
ASPG NQO1 FASLG HAMP CXCR4 RAD51 PPP2R1B RMI1 ANKRD26
SERPINA1 BRCA2 MECP2 CYP2E1 CDA CYP4F2 CXCR6 XPC POU1F1
MPO SETBP1 XRCC1 CYP3A4 REST TOP3A CXXC5 ZNF763 CYTB
SLC24A3 FKBP5 MYBPC3 CYP1A1 TLR4 HSPD1 DCK FANCA SH2B3
ZHX2 BRCA1 PDCD1 SLU7 SRSF2 CREBBP CRP BCL2 ARIH2
IL17F PDE9A KLF1 DNMT3B RAD52 PIM1 FPGS DHX15 ALK
MAP4 ESR1 LSD1
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Table 30: The list of variant-driven genes obtained by the proposed framework for prostate
cancer.
SNCA STAT3 AR YAP1 CDKN1B PIM1 FOXO1 EGFR ESR2
MYC MAPKAPK2 PTEN MDM2 RALA SH3BP1 RAC1 PDE8B NR3C1
AKT1 TRPV6 CHUK RPS6KB1 PARP1 PSMD5 PRL STAT5A SRC
CYR61 SQSTM1 PLK1 USP7 EEF1A2 CDKN1A IFI27 UGDH 8-Mar
ARF6 SYTL1 RAB8A TBC1D10A LCN2 EIF4E PALB2 TP53 MSN
BCHE RNASEL FOXA1 ADORA2A LPAR2 BMPR2 TRA HOXB13 IL6
CDK5 BDNF ABCB1 C3 TRIM27 LAMP1 ZFHX3 KLK3 RHOA
RNF19A ATM PRKDC ATR ERCC3 FANCA HDAC2 MLH3 NBN
IRS1 KLK4 KLK14 BUB1B KRAS BRCA1 HDAC1 TET1 IL4I1
KIT PKN1 HOTAIR KLK2 CNOT1 CYB5A USP10 AMD1 RPTOR
ACTR1B RNF41 ELAC2 AKT3 PSMD4 ULK1 TMEM37 BRCA2 CDK11B
SMAD4 KMT2D NOTCH4 SUMO4 SENP2 TP63 PRKD1 MARK2 RET
TGFBR2 HUWE1 MYO1C HIST2H3C CASP3 DHX15 PDPK1 EZH2 SPOP
FAM83G USP44 CHD1 CDC42 SUMO2 SENP6 ALOX12 KLF6 CTNNB1
PRKAA2 MAGEA11 HIST2H2AA3 KRT79 PAK2 HAT1 CXCL8 MAP2K1 CDK5RAP2
LIN28B GZMM CD40LG MAGEC3 EP300 HEY1 MLX NCOA3 CTC1
USP39 GSTK1 E2F1 HIF1A FOLH1 MCM3 MTOR PCA3 DBN1
NSD2 USF2 GSK3B C9orf3 ID4 RAB5A WDR35 ETV6 ETV7
ERG RASSF1 SLC19A1 MRNIP BAZ2A RAD50 MSR1 SEMA6B PIAS2
WDR77 MFSD2A CTSA ATP4A DAB2IP SKP2 IGF1 VEGFA CGB5
ABI1 KEAP1 TREX2 IL17RA AGAP2 MED25 HCFC1 ST8SIA4 XPR1
F2RL1 RAB11A GHRL FSD1 IGFBP2 CUL3 SPDEF NFKBIA REV3L
CTCF EWSR1 EFNA5 UXT MLPH S100A10 IFT81 FCF1 FGFR4
PIK3CA PIK3R1 EPHA5 ABL2 TRRAP MSH2 ELK1 ETS2 PAWR
TNFSF10 CASP8 ESR1 CD82 SATB2 GRK3 CREB1 GAPDH HSP90AA1
DNAH8 BRIP1 TSC2 FKBP4 IGF1R ATF3 CHRM3 HRAS BRD2
PPP6R2 TK1 PCSK1 MAP3K8 TARDBP APOBEC3G CHD4 FAT1 ERBB2
ETS1 USP2 CDK4 STK11 INTS6 NR2E1 KRT14 INF2 DAPK2
BRAF KDM4C CYP1A1 OTUB1 NCOR1 HSPA4 NCOA2 TBP PLXNB1
RHOD NFKB1 CXCR4 MAPK1 IL31RA DTYMK CDK1 SS18L1 COL18A1
MID1 PDE4D RPS6KB2 SERPINA1 PRPF31 DEFB109C FRMD6 MAPK8 ITGA9
ROCK2 SH3KBP1 CCND1 SIAH2 SH3RF1 CYP1B1 PLAT ERBB3 SLC1A2
RNASEH2A HSD3B1 SNRNP70 CYP17A1 GPRC6A BGLAP ACPP PSMD9 FGF9
APOE TRAM1 KRT6A BTG2 EHMT2 VDR PARD6A ANXA2 XPO1
PAK6 FASN CDKN2A KMT2C KMT2A NANOG ARF1 TNK2 MAPK14
RIT2 ABCB4 REPS2 AMPH SGK1 COX18 TERT SPTY2D1 CCL2
SDK1 LILRA3 ALS2CR12 TMPRSS2 APOB MSH6 TMEM38B JAZF1 PKHD1
GPX1 EPHX1 IL10RB ITGA2 CYP2R1 OAS1 MSMB SCARB1 FGFR2
HSD17B4 HTR3B HNF1B EPCAM AXIN2 FBN1 LEPR IL1B NDUFS2
ERCC1 DUT LINC00673 ORAI1 EFNB2 IGFBP3 PHLPP2 NAT2 MDM4
SHBG EPHB2 ABL1 IDH1 CDKAL1 TCF7L2 ADH1B GPRC5B PDLIM5
PKD1L3 GCKR ITGA6 IRX4 TERC SORT1 PPFIBP2 OCA2 HMGCR
OAS2 CCHCR1 ERCC2 KLF12 LDAH CHEK2 AARS2 TACSTD2 ALDH9A1
BCL11A NPHP1 NFAT5 THADA DKK3 ABCG2 CCDC78 LRSAM1 NKX3-1
IL10 FTO CYP24A1 CDH1 MGMT GSTP1 CYP19A1 EPAS1 APC
NOD2 CASR ADIPOQ PRMT6 GOLPH3L MAPT POR CDKN2B-AS1 SLC41A1
MC4R TNF XRCC1 CCR2 MLH1 NOS3 TGFB1 NQO1 MTHFR
PPARG RAD51 MC1R LIG4 CA4 XPC KDR TLR9 UGT2B15
ABCC4 SHMT1 FOXP4 CYP2E1 IL2 TLR5 TNFRSF11B COL1A1 PROM1
CCL5 FGF10 FOXO3 IL10RA G6PC2 IL1RN TBX1 PSCA SPINK5
GP6 MMP2 MRTFB VGLL3 EHBP1 ERAP1 XAGE3 CRP NRIP1
NSD1 BAG6 MSH5 POLB DHODH CCND2 LPL RFX6 MUTYH
CX3CR1 CDON P2RX7 FMN1 CYP2D6 MUC1 SLCO1B1 TNFRSF1A IRAK4
ZBTB10 AHR HAPLN1 TLR10 GRIK1 COMT WFS1 NEDD9 TLR1
IL21 SOD2 CTBP2 TLR4 BCL2 LCT SRD5A2 SLC22A3 TNS3
PCSK9 BIK OPRD1 FUT2 PEX14 FANCI NR5A2 LMTK2 SLC9C2
ALDH2 PRDM9 MMAB SIX1 ZNF652 ADIPOR1 RMST IRS2 APOC3
SETD7 MARCHF8 JAK2 PEX2 AMZ2 NAALADL2 JMJD1C TTC9 ASNA1
CBR1 HMGA2 NCOR2 HLA-DRB1 NOL10 CTDSPL MYO6 FRK UNC5D
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Table 31: The list of variant-driven genes obtained by the proposed framework for breast
cancer.
RPS6KB1 CHEK1 PIK3CA STAT3 TGM2 PARP1 EGFR CTCF TRIM28
ESR1 HRAS CAV1 RAC1 TAZ PRL EIF2S1 TP53 FXYD1
PRDX1 USP1 AKT1 PTEN SRC PIK3CG ANO1 MAPK8 PSMD5
IMMT GPR132 EPCAM RHOA SKP2 ABL1 ATM CTNNB1 MST1
BRCA1 MIR10B MTHFR TLN2 KEAP1 HIF1A PGR EIF2AK4 EHMT2
SYK GTF2B ELK1 MMP14 SOD2 ERBB2 AR BRCA2 PARD3
TRIM25 HPR CD44 CASP8 RELA IL1B ZHX2 RALGDS NCK1
NFKBIA RAB11A RHOC MAPK14 FGFR2 PTPN11 PIN1 STAT5A GSK3B
PPM1G PLD2 PIK3CD STIM1 ADAM17 TOX3 NOS3 PRKAA1 GUCY2F
NOX5 DECR1 ADARB1 PRNP SCN2A BST2 SLC9A1 ARF1 PICK1
POU5F1 SELENBP1 SEPHS1 TYRP1 BMPR1B ARHGEF1 BCR BRK1 TRIM62
MIR200C DHX58 CDH1 NUTF2 RAN MAP2K6 PKD1 CACNA1B CHEK2
PIK3CB KCNQ2 CD36 MDM2 CYB5A IKBKE NME1 RAB5A PDP1
GRIN1 AKT2 POLG HFM1 FHIT TGFB1 PAK4 TF MASTL
VAV1 FBXO28 RAF1 GPNMB EZH2 KMT2C PA2G4 NUB1 RAD51
LMNA ARF6 PTPN18 PSTPIP1 NR4A2 MAP2K5 MAP3K1 MAP2K4 PAK2
PAK1 CDC42 TRPV4 KCNJ11 GAS7 DICER1 MIR34A SELENOW PRKCE
CSF1 AKIP1 FLT4 RAB27A ARRB2 RAB24 SLC5A5 MST1R HSF1
PTPRJ ADCY1 LDLRAP1 ADCY2 SMAD3 HSP90AA1 MTOR CREB1 SH2B1
POT1 EEA1 PAFAH1B1 BCL2 BAX CCND1 MME BARD1 ZNF135
CSF2RA FBXW7 JAK2 MYC HSP90AB1 RRM1 FOXP3 LCK FGFR4
FOXA1 GJA1 PTK2 RIN1 PKD2 MSN EZR UMOD GRHL1
GRHL3 TP73 CFL1 GRIA1 SH3BP4 ACAP1 ACAP2 ASAP1 KRAS
PRKAB1 PXN SIRT6 FOXO3 LOX RAB7B PCNA AZIN1 CA1
CASP2 BECN1 OCRL MIEN1 SMN2 MED12 CDKN2A PLD1 PPP2R1A
FOXL2 CDK4 BDKRB1 YAP1 SFTPC TRIO TIAM1 FGF14 L3MBTL3
BAIAP2 TRPV1 ATF1 LMAN1 UQCRHL ADAM10 ADAMTS15 UIMC1 AMOTL1
MR1 PPARG ARSB RBBP8 RNF213 ABCE1 DNAH8 FANCI NEDD9
BCAR1 LAMB1 STARD8 RDX APP GAPDH IL4R SPHK1 CFTR
TLK2 GHR TUBB3 TSC22D3 LGALS4 APC2 AXIN1 COPS6 DNMT3A
WEE1 AGO1 TDP1 NEDD8 NAE1 PRKDC ZNF217 ZNF516 CTBP2
HDAC1 AMELX ITCH NEDD4L TOP1 MTA1 MTA2 POLR3K CKLF
GJB1 RYR1 NSF PLEK FGF2 AKAP10 RIOK2 FANCD2 CA2
IRF8 SCRIB DLC1 APAF1 RND1 S100A4 GPI ABCG2 HIVEP3
MAP1LC3A GNAS PLP1 CD24 STARD13 TRPM7 RIC8A PIK3C3 RAB33B
RAB1A RAB6A RAB2A AURKA INS HEBP1 CRH CRHR1 PTPRF
RPL27A PADI4 MUC5AC NQO1 RAB34 FMR1 DHX16 RAB7A HEY1
NOTCH1 CAMK2G DDX23 RAB22A ZAR1 CSNK1G1 TALDO1 ERN1 RAB4A
YIPF5 RABAC1 SRGAP2 PDCD10 TERT GRB2 DRG1 SYVN1 GALNT6
CALR MAPK8IP1 KCNJ2 NEDD4 FANCA TOE1 ESS2 P2RY2 VIM
TIPRL GLS PMP22 MAPK8IP3 CMTR1 DHX15 GAB1 KRT15 RNASE1
DCN CSF1R MUT MAPK1 RAC3 NCK2 ATL3 RHOQ LINC00310
WWOX CSNK2A1 CCNB1 SIRT1 PRRX1 KLF4 PLK4 COIL TET1
MED14 PRPF4B EPO SMAD4 RNPEP ACE ATAT1 CDK1 PRKCA
ADA2 CDK9 EIF2AK3 PTK2B TPT1 RAB35 PON1 ARL4A CHD1
VRK3 NRP1 PRRT2 MIB1 KAT5 ESRP2 SPRY2 CTTN SMURF2
MAPKAPK2 USF1 CPT1A CDKN1A TGFBR1 PARD6A BMP15 ERBB3 STAT2
SENP1 NOTCH3 PSEN1 FAAH MTA3 NUMB NANOG RAB23 FIP1L1
RAB8A RAB10 ARF4 HSPB1 SEC24D SVIL RUNX2 ARL8B BABAM2
ABCB1 POU1F1 GATA3 USF3 CYP2D6 SLX4 SDHB SDHD LEPR
ERCC1 NAT2 ACTN4 NRAS STK11 FGFR1 KCNQ1 ERCC2 ERBB4
APOB STAT1 MUTYH CLDN1 NBN GALNT12 ABCB6 MCM8 ABCC11
TCF4 XRCC1 XPA CASR PALB2 ATR PDGFRA VPS35 CYP2C8
MLH1 KCNE1 NOD2 CYP2E1 MEN1 SEMA3F SLCO1B1 CTLA4 MMP2
RAD51B GFAP KLHDC7A XRCC2 PHLDA3 ABCC1 U2AF1 SCN1A PITX2
UGT1A1 APOE COMT CYP2C19 AGTR1 SF3B1 FAM20A BRIP1 CELSR2
MSH2 LDLR WDR43 CUX1 ETV6 VDR RET COL1A1 NA
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Table 32: The complete list of variant-disease pairs identified by the proposed method and
the baseline method from the gold standard databases [29].
PMID Mutation Gold_standard Proposed_method Co-occurrence method
12023985 p|SUB|R|188|H breast neoplasms breast cancer breast cancer
12100746 p|SUB|V|89|L breast neoplasms breast cancer breast cancer
12516098 p|SUB|P|1315|L breast neoplasms breast cancer breast cancer
12602915 p|SUB|R|726|L breast neoplasms prostate cancer prostate cancer
12628588 p|SUB|Q|253|H breast neoplasms breast cancer breast cancer
12702523 p|SUB|R|72|P breast neoplasms breast cancer breast cancer
12786840 p|SUB|R|156|G breast neoplasms breast carcinoma breast carcinoma
12810666 p|SUB|L|1420|F breast neoplasms, ovarian neoplasms breast cancer breast cancer
12872252 p|SUB|Q|540|L breast neoplasms, ovarian neoplasms breast cancer breast cancer
12917204 p|SUB|L|546|V breast neoplasms breast cancer breast cancer
14683420 p|SUB|R|72|P breast neoplasms breast cancer breast cancer
15059511 p|SUB|P|359|L breast neoplasms breast cancer breast cancer
15170666 p|SUB|E|233|G breast neoplasms breast cancer breast cancer
16061562 p|SUB|C|645|R breast neoplasms, ovarian neoplasms ovarian tumor ovarian tumor
16168123 p|SUB|S|384|F breast neoplasms breast cancer breast cancer
16333312 p|SUB|V|507|M breast neoplasms, ovarian neoplasms breast cancer breast cancer
16652348 c|SUB|C|146|G breast neoplasms breast cancer breast cancer
16760288 p|SUB|F|486|L breast neoplasms, ovarian neoplasms breast cancer breast cancer
16760288 p|SUB|N|550|H breast neoplasms, ovarian neoplasms breast cancer breast cancer
16760288 p|SUB|Y|179|C breast neoplasms, ovarian neoplasms breast cancer breast cancer
16822847 p|SUB|G|388|R breast neoplasms breast cancer breast cancer
16825437 p|SUB|S|558|P breast neoplasms breast cancer breast cancer
17001622 p|SUB|V|2424|G breast neoplasms breast cancer breast cancer
17217814 p|SUB|V|158|M breast neoplasms breast cancer breast cancer
17427234 p|SUB|R|248|W neuroblastoma, li-fraumeni syndrome neuroblastoma neuroblastoma
17541742 p|SUB|R|213|Q breast neoplasms, ovarian neoplasms li-fraumeni syndrome li-fraumeni syndrome
17541742 p|SUB|R|290|H breast neoplasms, ovarian neoplasms li-fraumeni-like li-fraumeni-like
17553133 p|SUB|K|303|R breast neoplasms breast cancer breast cancer
17574969 p|SUB|R|1699|W phyllodes tumor tumor of the breast tumor of the breast
17848578 p|SUB|Q|564|H breast neoplasms, ovarian neoplasms,
endometrial tumors
endometrial tumors endometrial tumors
17848578 p|SUB|V|695|L breast neoplasms, ovarian neoplasms,
endometrial tumors
endometrial tumors endometrial tumors
18241035 p|SUB|D|301|H breast neoplasms breast cancers breast cancers
18241035 p|SUB|G|479|E breast neoplasms breast cancers breast cancers
18241035 p|SUB|L|792|F breast neoplasms breast cancers breast cancers
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18565893 p|SUB|S|707|P breast neoplasms, thyroid neoplasms,
ENDOCRINE GLAND NEOPLASMS
breast cancer breast cancer
10477429 p|SUB|M|133|T breast neoplasms, li-fraumeni syndrome breast sarcoma NA
10485478 p|SUB|G|1449|V breast neoplasms, hepatocellular
carcinoma
breast cancers NA
10485478 p|SUB|G|1464|E breast neoplasms, hepatocellular
carcinoma
breast cancers NA
10485478 p|SUB|I|1572|T breast neoplasms, hepatocellular
carcinoma
breast cancers NA
10485478 p|SUB|Q|1445|H breast neoplasms, hepatocellular
carcinoma
breast cancers NA
10534763 p|SUB|G|2765|S breast neoplasms breast cancer NA
10547570 p|SUB|R|273|C phyllodes tumor phyllodes tumours NA
11212236 p|SUB|L|452|M breast neoplasms breast tumor NA
11212236 p|SUB|N|435|S breast neoplasms breast tumor NA
11212236 p|SUB|V|387|M breast neoplasms breast tumor NA
11212236 p|SUB|V|447|A breast neoplasms breast tumor NA
12100746 p|SUB|A|49|T breast neoplasms breast cancer NA
12645254 p|SUB|M|1652|I breast neoplasms, ovarian neoplasms ovarian cancer NA
12645254 p|SUB|S|1613|G breast neoplasms, ovarian neoplasms ovarian cancer NA
12645254 p|SUB|W|1837|R breast neoplasms, ovarian neoplasms ovarian cancer NA
12649339 p|SUB|S|215|I breast neoplasms breast cancer NA
12668615 p|SUB|D|213|N breast neoplasms breast cancer NA
12872252 p|SUB|V|524|I breast neoplasms, ovarian neoplasms breast cancer NA
15059511 p|SUB|N|289|H breast neoplasms breast cancer NA
15059511 p|SUB|N|371|H breast neoplasms breast cancer NA
15059511 p|SUB|N|991|D breast neoplasms breast cancer NA
15101044 c|SUB|T|2572|C breast neoplasms breast cancer NA
15101044 p|SUB|P|1054|R breast neoplasms breast cancer NA
15235021 p|SUB|R|732|Q stomach neoplasms, breast neoplasms breast cancers NA
15235021 p|SUB|W|409|R stomach neoplasms, breast neoplasms breast cancers NA
15649950 p|SUB|P|85|L breast neoplasms breast cancer NA
15665273 p|SUB|S|148|A breast neoplasms breast cancer NA
15665273 p|SUB|S|251|A breast neoplasms breast cancer NA
15665273 p|SUB|S|288|A breast neoplasms breast cancer NA
15870154 p|SUB|T|461|D breast neoplasms breast cancer NA
16061562 p|SUB|C|557|S ovarian neoplasms ovarian tumour NA
16061562 p|SUB|I|738|V breast neoplasms ovarian tumour NA
16061562 p|SUB|S|761|N breast neoplasms, uterine neoplasms ovarian tumours NA
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16123141 p|SUB|T|135|E breast neoplasms breast cancer NA
16280053 p|SUB|P|47|A breast neoplasms breast cancer NA
16503999 p|SUB|C|282|Y breast neoplasms breast cancer NA
16563154 c|SUB|T|309|G breast neoplasms breast cancer NA
16652348 p|SUB|F|858|L breast neoplasms breast cancer NA
16969499 p|SUB|S|1841|N breast neoplasms, ovarian neoplasms breast tumorigenesis NA
17130833 p|SUB|V|143|A breast neoplasms breast cancer NA
17317153 p|SUB|P|871|L breast neoplasms breast cancers NA
17493881 p|SUB|V|1833|M breast neoplasms, ovarian neoplasms hereditary
breast/ovarian cancer
NA
17531442 p|SUB|S|1143|A breast neoplasms breast cancer NA
17531442 p|SUB|S|1280|A breast neoplasms breast cancer NA
17550384 p|SUB|P|350|R breast carcinoma, colorectal neoplasms,
non-small-cell lung carcinoma, gastric
carcinoma
breast carcinoma NA
17550384 p|SUB|R|389|C breast carcinoma, colorectal neoplasms,
non-small-cell lung carcinoma, gastric
carcinoma
breast carcinoma NA
17889706 p|SUB|S|255|R breast neoplasms breast tumors NA
18036263 p|SUB|A|1708|V breast neoplasms breast cancer NA
18036263 p|SUB|G|1738|R breast neoplasms breast cancer NA
18036263 p|SUB|R|1699|Q breast neoplasms breast cancer NA
18083510 p|SUB|A|238|V breast neoplasms ovarian cancer NA
18083510 p|SUB|R|259|H breast neoplasms ovarian cancer NA
18083510 p|SUB|S|313|G breast neoplasms ovarian cancer NA
18186519 p|SUB|G|12|S breast neoplasms, colon neoplasms colon and breast cancer NA
18186519 p|SUB|G|12|V breast neoplasms, colon neoplasms colon and breast cancer NA
18186519 p|SUB|V|600|E breast neoplasms, colon neoplasms colon and breast cancer NA




18332865 p|SUB|C|124|S breast neoplasms breast cancer NA
18332865 p|SUB|G|129|E breast neoplasms breast cancer NA
18372405 p|SUB|A|111|D breast neoplasms breast cancer NA
18372405 p|SUB|G|160|R breast neoplasms breast cancer NA
18375489 p|SUB|E|542|K breast neoplasms, colorectal neoplasms,
lung neoplasms, melanoma
colorectal cancer NA
18431743 p|SUB|F|31|I ovarian neoplasms breast cancer NA
18431743 p|SUB|N|372|H ovarian neoplasms breast cancer NA
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9407971 p|SUB|R|175|H breast neoplasms breast cancer NA
9407971 p|SUB|R|249|S breast neoplasms breast cancer NA
9407971 p|SUB|R|273|H breast neoplasms breast cancer NA
9806478 p|SUB|A|148|T melanoma melanoma NA
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Table 33: The complete list of variants automatically extracted from 10,000 random arti-
cles and also manually reviewed and validated. False positive means the extracted entity
is not a variant and it is wrongly identified as a variant.
PMCID NORMALIZED_FORM TYPE MENTIONED FALSE POSITIVE?
PMC4502233 p|SUB|R|4810|K ProteinMutation p.R4810K NO
PMC4565919 p|SUB|L|90|M ProteinMutation L90M NO
PMC4876505 c|SUB|G|93|A DNAMutation G93A NO
PMC2684265 p|SUB|P|504|S ProteinMutation P504S NO
PMC3666908 p|SUB|V|158|M ProteinMutation Val158Met NO
PMC4718276 p|SUB|V|600|E ProteinMutation V600E NO
PMC4962770 p|SUB|V|66|M ProteinMutation Val66Met NO
PMC4991467 rs6295 SNP rs6295 NO
PMC5012569 p|SUB|P|301|S ProteinMutation P301S NO
PMC1247523 c|SUB|G|1800|A DNAMutation G1800A YES
PMC2188802 c|SUB|C|200|T DNAMutation C/T200 YES
PMC2584175 c|SUB|A|1|C DNAMutation A1C YES
PMC2720913 p|SUB|E||T ProteinMutation E/T YES
PMC2829413 c|SUB|A|1|C DNAMutation A1C YES
PMC2841238 c|SUB|G|1311|A DNAMutation G1311A YES
PMC2841238 c|SUB|G|1329|A DNAMutation G1329A YES
PMC2841238 c|SUB|G|1379|A DNAMutation G1379A YES
PMC2841238 c|SUB|G|1316|A DNAMutation G1316A YES
PMC2875450 c|SUB|A|1|C DNAMutation A1C YES
PMC2889782 c|SUB|A|1|C DNAMutation A1C YES
PMC2915039 p|SUB|H|14|A ProteinMutation H14A YES
PMC2915039 p|SUB|H|14|C ProteinMutation H14C YES
PMC2959805 p|SUB|H|11|A ProteinMutation H11A YES
PMC2968464 p|SUB|H|11|A ProteinMutation H11A YES
PMC2968464 p|SUB|H|11|C ProteinMutation H11C YES
PMC2968464 p|SUB|H|12|A ProteinMutation H12A YES
PMC2968464 p|SUB|H|12|C ProteinMutation H12C YES
PMC2968899 p|SUB|H|10|A ProteinMutation H10A YES
PMC2969907 p|SUB|H|23|A ProteinMutation H23A YES
PMC2969907 p|SUB|H|14|A ProteinMutation H14A YES
PMC2969907 p|SUB|H|20|A ProteinMutation H20A YES
PMC2969907 p|SUB|H|26|A ProteinMutation H26A YES
PMC2969907 p|SUB|H|18|A ProteinMutation H18A YES
PMC2969907 p|SUB|H|29|A ProteinMutation H29A YES
PMC2969907 p|SUB|H|28|A ProteinMutation H28A YES
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PMC2969907 p|SUB|H|19|A ProteinMutation H19A YES
PMC2969907 p|SUB|H|22|A ProteinMutation H22A YES
PMC2969907 p|SUB|H|22|C ProteinMutation H22C YES
PMC2969907 p|SUB|H|27|A ProteinMutation H27A YES
PMC2969907 p|SUB|H|13|A ProteinMutation H13A YES
PMC2969907 p|SUB|H|11|A ProteinMutation H11A YES
PMC2969907 p|SUB|H|12|A ProteinMutation H12A YES
PMC2969907 p|SUB|H|31|A ProteinMutation H31A YES
PMC2969907 p|SUB|H|31|C ProteinMutation H31C YES
PMC2979928 p|SUB|H|11|A ProteinMutation H11A YES
PMC2979928 p|SUB|H|14|A ProteinMutation H14A YES
PMC2979928 p|SUB|H|14|C ProteinMutation H14C YES
PMC2979928 p|SUB|H|15|A ProteinMutation H15A YES
PMC2979928 p|SUB|H|15|C ProteinMutation H15C YES
PMC2983608 p|SUB|H|20|A ProteinMutation H20A YES
PMC2983608 p|SUB|H|20|C ProteinMutation H20C YES
PMC2992198 c|SUB|A|1|C DNAMutation A1C YES
PMC3005448 c|SUB|A|1|C DNAMutation A1C YES
PMC3005479 c|SUB|A|1|C DNAMutation A1C YES
PMC3007219 p|SUB|H|13|A ProteinMutation H13A YES
PMC3007219 p|SUB|H|13|C ProteinMutation H13C YES
PMC3007494 p|SUB|H|23|A ProteinMutation H23A YES
PMC3007494 p|SUB|H|24|A ProteinMutation H24A YES
PMC3007494 p|SUB|H|24|C ProteinMutation H24C YES
PMC3007494 p|SUB|H|23|C ProteinMutation H23C YES
PMC3007494 p|SUB|H|23|D ProteinMutation H23D YES
PMC3007494 p|SUB|H|24|D ProteinMutation H24D YES
PMC3007494 p|SUB|H|24|E ProteinMutation H24E YES
PMC3007494 p|SUB|H|24|F ProteinMutation H24F YES
PMC3008083 p|SUB|H|16|A ProteinMutation H16A YES
PMC3008083 p|SUB|H|16|C ProteinMutation H16C YES
PMC3008083 p|SUB|H|17|A ProteinMutation H17A YES
PMC3008083 p|SUB|H|17|C ProteinMutation H17C YES
PMC3008083 p|SUB|H|32|A ProteinMutation H32A YES
PMC3008083 p|SUB|H|32|C ProteinMutation H32C YES
PMC3009229 p|SUB|H|10|A ProteinMutation H10A YES
PMC3009229 p|SUB|H|11|A ProteinMutation H11A YES
PMC3009229 p|SUB|H|11|C ProteinMutation H11C YES
PMC3009229 p|SUB|H|12|A ProteinMutation H12A YES
PMC3009229 p|SUB|H|12|C ProteinMutation H12C YES
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PMC3009229 p|SUB|H|13|A ProteinMutation H13A YES
PMC3009229 p|SUB|H|14|A ProteinMutation H14A YES
PMC3009229 p|SUB|H|14|C ProteinMutation H14C YES
PMC3009229 p|SUB|H|15|A ProteinMutation H15A YES
PMC3009229 p|SUB|H|15|C ProteinMutation H15C YES
PMC3011503 p|SUB|H|10|A ProteinMutation H10A YES
PMC3011503 p|SUB|H|10|C ProteinMutation H10C YES
PMC3011503 p|SUB|H|11|A ProteinMutation H11A YES
PMC3011503 p|SUB|H|11|C ProteinMutation H11C YES
PMC3011503 p|SUB|H|13|A ProteinMutation H13A YES
PMC3011503 p|SUB|H|13|C ProteinMutation H13C YES
PMC3011503 p|SUB|H|14|A ProteinMutation H14A YES
PMC3011503 p|SUB|H|14|C ProteinMutation H14C YES
PMC3011503 p|SUB|H|15|A ProteinMutation H15A YES
PMC3011503 p|SUB|H|15|C ProteinMutation H15C YES
PMC3011503 p|SUB|H|30|A ProteinMutation H30A YES
PMC3011503 p|SUB|H|30|C ProteinMutation H30C YES
PMC3011503 p|SUB|H|31|A ProteinMutation H31A YES
PMC3011503 p|SUB|H|31|C ProteinMutation H31C YES
PMC3011503 p|SUB|H|32|A ProteinMutation H32A YES
PMC3011503 p|SUB|H|32|C ProteinMutation H32C YES
PMC3011503 p|SUB|H|34|A ProteinMutation H34A YES
PMC3011503 p|SUB|H|34|C ProteinMutation H34C YES
PMC3011503 p|SUB|H|35|A ProteinMutation H35A YES
PMC3011503 p|SUB|H|35|C ProteinMutation H35C YES
PMC3011503 p|SUB|H|36|A ProteinMutation H36A YES
PMC3011503 p|SUB|H|36|C ProteinMutation H36C YES
PMC3012188 c|SUB|A|1|C DNAMutation A1C YES
PMC3030744 c|SUB|G|1575|A DNAMutation G1575A YES
PMC3051471 p|SUB|H|31|A ProteinMutation H31A YES
PMC3051471 p|SUB|H|32|A ProteinMutation H32A YES
PMC3051471 p|SUB|H|33|A ProteinMutation H33A YES
PMC3051471 p|SUB|H|34|A ProteinMutation H34A YES
PMC3051517 p|SUB|H|14|A ProteinMutation H14A YES
PMC3051517 p|SUB|H|13|A ProteinMutation H13A YES
PMC3051517 p|SUB|H|12|A ProteinMutation H12A YES
PMC3088031 p|SUB|T|9|S ProteinMutation T9S YES
PMC3122477 c|DEL|| DNAMutation DELTA YES
PMC3139590 RS800 SNP RS800 YES
PMC3164897 5bins DNAMutation 5 bins YES
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PMC3164897 3bins DNAMutation 3 bins YES
PMC3196552 c|SUB|S|-2600|H DNAMutation S-2600H YES
PMC3202145 c|SUB|C|31|G DNAMutation C31G YES
PMC3225014 c|SUB|GGCA|6|C DNAMutation GGCA6C YES
PMC3225014 c|SUB|CCGT|6|G DNAMutation CCGT6G YES
PMC3275195 p|SUB|H|10|A ProteinMutation H10A YES
PMC3275195 p|SUB|H|11|A ProteinMutation H11A YES
PMC3275195 p|SUB|H|12|A ProteinMutation H12A YES
PMC3275195 p|SUB|H|14|A ProteinMutation H14A YES
PMC3275195 p|SUB|H|16|A ProteinMutation H16A YES
PMC3275195 p|SUB|H|17|A ProteinMutation H17A YES
PMC3275195 p|SUB|H|18|A ProteinMutation H18A YES
PMC3297250 p|SUB|H|13|A ProteinMutation H13A YES
PMC3297250 p|SUB|H|14|A ProteinMutation H14A YES
PMC3353114 p|SUB|D|125|I ProteinMutation D 125I YES
PMC3537756 c|SUB|G|3|A DNAMutation G3A YES
PMC3551769 p|SUB|V|36|G ProteinMutation V36G YES
PMC3588815 p|SUB|H|11|A ProteinMutation H11A YES
PMC3588815 p|SUB|H|12|A ProteinMutation H12A YES
PMC3588815 p|SUB|H|19|A ProteinMutation H19A YES
PMC3588815 p|SUB|H|19|C ProteinMutation H19C YES
PMC3588815 p|SUB|H|20|A ProteinMutation H20A YES
PMC3588815 p|SUB|H|20|C ProteinMutation H20C YES
PMC3588815 p|SUB|H|21|A ProteinMutation H21A YES
PMC3588815 p|SUB|H|21|C ProteinMutation H21C YES
PMC3598566 p|SUB|V|150|T ProteinMutation 150 V/T YES
PMC3721223 g|SUB|A|80915|G DNAMutation A80915G YES
PMC3841629 c|SUB|A|1|C DNAMutation A1C YES
PMC3868173 MOT>LUM ProteinMutation MOT >LUM YES
PMC3881066 p|SUB|A|30|P ProteinMutation A30P YES
PMC3927678 p|SUB|H|379|UF ProteinMutation H 379 UF YES
PMC3949696 c|SUB|A|1|C DNAMutation A1C YES
PMC3998480 p|SUB|H|12|A ProteinMutation H12A YES
PMC4013063 p|SUB|M|20|A ProteinMutation M20A YES
PMC4013537 c|SUB|A|1|C DNAMutation A1C YES
PMC4023268 c|SUB|A|86|C DNAMutation A86C YES
PMC4051029 p|SUB|H|12|A ProteinMutation H12A YES
PMC4051064 p|SUB|H|10|A ProteinMutation H10A YES
PMC4051064 p|SUB|H|10|C ProteinMutation H10C YES
PMC4051064 p|SUB|H|11|A ProteinMutation H11A YES
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PMC4051064 p|SUB|H|11|C ProteinMutation H11C YES
PMC4051064 p|SUB|H|12|A ProteinMutation H12A YES
PMC4051064 p|SUB|H|13|A ProteinMutation H13A YES
PMC4051064 p|SUB|H|16|A ProteinMutation H16A YES
PMC4051064 p|SUB|H|16|C ProteinMutation H16C YES
PMC4051064 p|SUB|H|17|A ProteinMutation H17A YES
PMC4051064 p|SUB|H|17|C ProteinMutation H17C YES
PMC4051064 p|SUB|H|18|A ProteinMutation H18A YES
PMC4051064 p|SUB|H|18|C ProteinMutation H18C YES
PMC4051074 c|SUB|C|28|A DNAMutation C28A YES
PMC4051074 p|SUB|H|10|A ProteinMutation H10A YES
PMC4051074 c|SUB|C|11|A DNAMutation C11A YES
PMC4051074 p|SUB|H|26|A ProteinMutation H26A YES
PMC4051074 p|SUB|H|27|A ProteinMutation H27A YES
PMC4051074 c|SUB|C|29|A DNAMutation C29A YES
PMC4051074 p|SUB|H|29|A ProteinMutation H29A YES
PMC4051074 c|SUB|C|30|A DNAMutation C30A YES
PMC4051074 p|SUB|H|30|A ProteinMutation H30A YES
PMC4051074 c|SUB|C|31|A DNAMutation C31A YES
PMC4051074 p|SUB|H|31|A ProteinMutation H31A YES
PMC4051074 c|SUB|C|32|A DNAMutation C32A YES
PMC4051074 p|SUB|H|32|A ProteinMutation H32A YES
PMC4051074 p|SUB|H|33|A ProteinMutation H33A YES
PMC4139185 p|SUB|C|13|N ProteinMutation C13 N YES
PMC4153077 p|SUB|A|16|S ProteinMutation A 16S YES
PMC4257264 p|SUB|N|11|C ProteinMutation N11C YES
PMC4257264 c|SUB|C|11|A DNAMutation C11A YES
PMC4257264 c|SUB|C|5|A DNAMutation C5A YES
PMC4257264 p|SUB|N|11|D ProteinMutation N11D YES
PMC4257264 c|SUB|C|6|A DNAMutation C6A YES
PMC4257264 p|SUB|H|11|A ProteinMutation H11A YES
PMC4257264 p|SUB|H|11|C ProteinMutation H11C YES
PMC4257264 p|SUB|H|12|C ProteinMutation H12C YES
PMC4257264 p|SUB|H|13|C ProteinMutation H13C YES
PMC4257264 p|SUB|H|21|C ProteinMutation H21C YES
PMC4257264 p|SUB|H|31|C ProteinMutation H31C YES
PMC4257264 p|SUB|H|32|C ProteinMutation H32C YES
PMC4257264 p|SUB|H|41|C ProteinMutation H41C YES
PMC4257264 p|SUB|H|42|C ProteinMutation H42C YES
PMC4257264 p|SUB|H|51|C ProteinMutation H51C YES
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PMC4257264 p|SUB|H|52|C ProteinMutation H52C YES
PMC4257264 p|SUB|H|12|D ProteinMutation H12D YES
PMC4257264 p|SUB|H|11|D ProteinMutation H11D YES
PMC4257264 p|SUB|H|21|D ProteinMutation H21D YES
PMC4257264 p|SUB|H|13|D ProteinMutation H13D YES
PMC4257264 p|SUB|H|14|D ProteinMutation H14D YES
PMC4257264 p|SUB|H|31|D ProteinMutation H31D YES
PMC4257264 p|SUB|H|32|D ProteinMutation H32D YES
PMC4257264 p|SUB|H|41|D ProteinMutation H41D YES
PMC4257264 p|SUB|H|42|D ProteinMutation H42D YES
PMC4257264 p|SUB|H|51|D ProteinMutation H51D YES
PMC4257264 p|SUB|H|52|D ProteinMutation H52D YES
PMC4320108 p|SUB|T|17|N ProteinMutation T17N YES
PMC4327586 p|SUB|S|010111|C ProteinMutation S010111C YES
PMC4329618 c|SUB|G|1322|A DNAMutation G1322A YES
PMC4329618 c|SUB|G|1312|A DNAMutation G1312A YES
PMC4329618 c|SUB|G|1367|C DNAMutation G1367C YES
PMC4329618 c|SUB|G|1316|A DNAMutation G1316A YES
PMC4370234 p.136] ProteinMutation p. 136] YES
PMC4372839 p|SUB|E|200|V ProteinMutation E200V YES
PMC4378971 c|SUB|T||C DNAMutation T/C YES
PMC4384578 p|SUB|H|10|A ProteinMutation H10A YES
PMC4384578 p|SUB|H|10|C ProteinMutation H10C YES
PMC4384578 p|SUB|H|11|A ProteinMutation H11A YES
PMC4384578 p|SUB|H|11|C ProteinMutation H11C YES
PMC4384578 p|SUB|H|12|A ProteinMutation H12A YES
PMC4384578 p|SUB|H|12|C ProteinMutation H12C YES
PMC4384578 p|SUB|H|13|C ProteinMutation H13C YES
PMC4384578 p|SUB|H|13|D ProteinMutation H13D YES
PMC4384578 p|SUB|H|13|E ProteinMutation H13E YES
PMC4384578 p|SUB|H|13|F ProteinMutation H13F YES
PMC4384578 p|SUB|H|13|A ProteinMutation H13A YES
PMC4433076 c|SUB|A|1|C DNAMutation A1C YES
PMC4439532 c|SUB|A|1|C DNAMutation A1C YES
PMC4462250 p|SUB|L||T ProteinMutation L/T YES
PMC4465688 c|SUB|C|3|G DNAMutation C3G YES
PMC4513483 p|SUB|A|10|V ProteinMutation A10 V YES
PMC4517832 c|SUB|C|-46|A DNAMutation C-46A YES
PMC4530960 c|SUB|A|7|T DNAMutation A 7T YES
PMC4592593 c|SUB|GC|-9|A DNAMutation GC-9A YES
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PMC4631937 p|SUB|P|2714|H ProteinMutation P2714H YES
PMC4644923 p|SUB|G|12|L ProteinMutation G12L YES
PMC4644923 p|SUB|G|12|H ProteinMutation G12H YES
PMC4644923 p|SUB|G|30|L ProteinMutation G30L YES
PMC4644923 p|SUB|H|23|R ProteinMutation H23R YES
PMC4682137 p|SUB|R|6|G ProteinMutation R6G YES
PMC4719921 p|SUB|H|21|A ProteinMutation H21A YES
PMC4719921 p|SUB|H|21|C ProteinMutation H21C YES
PMC4719921 p|SUB|H|22|A ProteinMutation H22A YES
PMC4719921 p|SUB|H|22|C ProteinMutation H22C YES
PMC4719921 p|SUB|H|43|A ProteinMutation H43A YES
PMC4719921 p|SUB|H|43|C ProteinMutation H43C YES
PMC4719921 p|SUB|H|44|A ProteinMutation H44A YES
PMC4719921 p|SUB|H|44|C ProteinMutation H44C YES
PMC4745523 p|SUB|G|25|N ProteinMutation G25N YES
PMC4772241 c|SUB|T|2|C DNAMutation T2C YES
PMC4840265 c|SUB|TC|-202|A DNAMutation TC-202A YES
PMC4851292 p|SUB|S|25|N ProteinMutation S25N YES
PMC4971855 p|SUB|H|13|A ProteinMutation H13A YES
PMC4971855 p|SUB|H|14|A ProteinMutation H14A YES
PMC4971855 p|SUB|H|31|A ProteinMutation H31A YES
PMC4971855 p|SUB|H|31|C ProteinMutation H31C YES
PMC5055046 c|SUB|C|10|AA DNAMutation C10AA YES
PMC5055046 c|SUB|C|09|A DNAMutation C09A YES
PMC5055046 c|SUB|A|1|C DNAMutation A1C YES
PMC5059018 p|SUB|V|103|C ProteinMutation V103C YES
PMC5088442 c|SUB|A|41|G DNAMutation A 41G YES
PMC5118020 p|SUB|T|40|S ProteinMutation T40S YES
PMC5119779 c|DUP|[19||[22][51][52][53][54][55]DNAMutation [19] [22] [51] [52] [53]
[54] [55]
YES
PMC5146877 p|SUB|Q|1000|P ProteinMutation Q1000P YES
PMC5244540 c|SUB|A|2|C DNAMutation A2 to C YES
PMC5290578 p|SUB|H|10|A ProteinMutation H10A YES
PMC5290578 p|SUB|S|2|C ProteinMutation S2C YES
PMC5290578 p|SUB|H|11|A ProteinMutation H11A YES
PMC5290578 p|SUB|H|12|A ProteinMutation H12A YES
PMC5290578 p|SUB|H|13|A ProteinMutation H13A YES
PMC5290578 p|SUB|H|13|C ProteinMutation H13C YES
PMC5319737 c|SUB|CT|-90|A DNAMutation CT-90A YES
PMC5319737 c|SUB|CT|90|A DNAMutation CT90A YES
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PMC5357070 c|SUB|A|1|C DNAMutation A1C YES
PMC5409166 c|SUB|A|1|C DNAMutation A1C YES
PMC5466104 p|SUB|K|550|X ProteinMutation K550X YES
PMC5523872 p|SUB|T|28|N ProteinMutation T28N YES
PMC5523872 p|SUB|T|27|N ProteinMutation T27N YES
PMC5523872 p|SUB|T|37|N ProteinMutation T37N YES
PMC5603897 p|SUB|M|062|X ProteinMutation M062X YES
PMC5631406 c|SUB|C||T DNAMutation C/T YES
PMC5657054 |SUB|DIS|2001|SEP ProteinMutation Dis 2001 Sep YES
PMC56607 |[||76 DNAMutation [76] YES
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In spite of the efforts in developing and maintaining accurate variant databases, a large
number of disease-associated variants are still hidden in the biomedical literature. Cura-
tion of the biomedical literature in an effort to extract this information is a challenging
task due to i) the complexity of natural language processing, ii) inconsistent use of stan-
dard recommendations for variant description, and iii) the lack of clarity and consistency
in describing the variant-genotype-phenotype associations in the biomedical literature. In
this article, we employ text mining and word cloud analysis techniques to address these
challenges. The proposed framework extracts the variant-gene-disease associations from
the full-length biomedical literature and designs an evidence-based variant-driven gene
panel for a given condition. We validate the identified genes by showing their diagnos-
tic abilities to predict the patients’ clinical outcomes on several independent validation
cohorts. As representative examples, we present our results for acute myeloid leukemia
(AML), breast cancer, and prostate cancer. We compare these panels with other variant-
driven gene panels obtained from Clinvar, Mastermind, and others from literature, as well
84
as with a panel identified with a classical differentially expressed genes (DEGs) approach.
The results show that the panels obtained by the proposed framework yield better results
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